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Similar to many cancers, pancreatic cancer (PDA) assumes an altered metabolic state 
that is designed to support the manufacture of macromolecules necessary for cell division. For 
example, membrane synthesis from lipid precursors is dependent on de novo fatty acid 
synthesis (dnFAS), a pathway that is upregulated in many cancers. The rate-limiting enzyme of 
dnFAS is fatty acid synthase (FASN), an enzyme that is overexpressed in cancer but found at 
very low levels in normal tissues. Here we demonstrate that fatty acid synthase (FASN) 
inhibition using novel small molecule inhibitor IPI-9119 induces apoptosis in FASN 
overexpressing epithelial cells of a pre-clinical pancreatic cancer mouse model (KPC). We also 
provide evidence that FASN inhibition insensitivity in PDA cells is due to flux through 
scavenging pathways, particularly macropinocytosis. We initially hypothesized that FASN 
overexpression is a survival strategy for PDA epithelial cells through which they acclimate to a 
low nutrient microenvironment. Indeed, K-ras driven metabolic reprograming has been shown to 
increase flux through the dnFAS pathway indicating that PDA cells should rely heavily on FASN 
activity. Surprisingly we found that PDA cell lines are minimally affected by FASN inhibition and 
rely chiefly on scavenging pathways. In vitro cells displayed a dependency on lysosomal 
function, determined using lysosomal inhibitor chloroquine (CQ). Dual therapy with FASN 
inhibitor, IPI-9119, and lysosomal inhibitor, CQ, increased apoptosis and decreased cell viability 
in human PDA cell lines and in bulk KPfl/flC PDA tumors. Our findings suggest that mutated 
epithelial tumor cells overexpress FASN and that these oncogenic cells can be specifically 
targeted using FASN inhibition. Our findings in regards to scavenging pathways demonstrate 
 that PDA is reliant on lysosomal activity and may utilize both autophagy and macropinocytosis 
to maintain lipid levels in addition to dnFAS. Dual therapy with a FASN inhibitor and a lysosomal 
inhibitor induces apoptosis in PDA cell lines regardless of their sensitivity to FASN inhibition 
alone indicating that this therapeutic strategy, dual treatment with lysosomal inhibitors and 
FASN inhibitors, should be further developed. Our major conclusions from this work are: (1) that 
PDA is not solely dependent on FASN activity for lipid maintenance but short-term inhibition 
results in targeted apoptosis in FASN expressing cells, in vivo. (2) Lipid scavenging pathway 
macropinocytosis accounts for primary resistance to FASN inhibition in vitro, although 
autophagy may also contribute. (3) Dual inhibition of FASN and lysosomal function induces 
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Chapter	  1	  –	  Pancreatic	  cancer	  
Introduction	  to	  pancreatic	  cancer	  	  
 
In 2017, an estimated 53,670 people in the United States will be diagnosed with 
pancreatic cancer, predominantly pancreatic ductal adenocarcinoma (PDA) which is the most 
lethal variant (American Cancer Society 2017). Pancreatic cancer is the third leading cause of 
US cancer-related deaths and has the lowest survival rate of any major cancer with a 5-year 
survival of just 8% (American Cancer Society 2017). The average survival after diagnosis is 
merely 6 months and most patients succumb to their disease within a year. For the 80-85% who 
present with unresectable disease, the only widely used therapeutic regimens are based on 
combinations of genotoxic therapeutics offering minimal survival improvement and slight 
symptomatic relief. No targeted therapy to date has shown broad efficacy against PDA. Indeed, 
the single common driver gene found in PDA, oncogenic K-ras (found in 95% of cases) is a 
notoriously poor drug target. Targeting the mutational profile of PDA has been largely 
unsuccessful, prompting research into alternative strategies. One such approach is to target 
critical biological programs such as metabolism and cell survival. As is true for many cancers, 
PDA undergoes metabolic reprograming, an oncogenic survival mechanism designed to support 
production of the macromolecules necessary for cell division. Therapeutic exploitation of this 
process is an area of interest in cancer biology as targeting this vulnerability could prove 
beneficial to patients.  
Pancreatic	  cancer	  classification	  
 
Pancreatic tumors can be classified as endocrine or exocrine based on the cell of origin; 
hormone producing or enzyme producing cells of the pancreas respectively (Sousa and 
Kimmelman 2014). Exocrine cancers are far more common making up 94% of pancreatic 
cancers (Siegel, Miller, and Jemal 2017). Pancreatic neuroendocrine tumors (PNETs), the 
second most common pancreatic malignancy (6%), arise from the secretory cells that make up 
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the Islets of Langerhans (Asa 2011). PNETs are further subdivided based on whether they show 
signs of hormone production, with “functional” tumors categorized based on the type of hormone 
produced (Asa 2011). Histologically, endocrine tumors have characteristic round cells with a 
granular cytoplasm, due to accumulation of mitochondria, as well as chromatin that has the 
appearance of  “salt and pepper” (Hackeng et al. 2016). In terms of gross morphology, PNETs 
are soft tumors that are red or white (Hackeng et al. 2016). Patients with PNETs have a better 
prognosis than those with exocrine tumors, including PDA (Hackeng et al. 2016). 
Exocrine tumors include those that originate from either the ductal or acinar cells of the 
exocrine pancreas, with ductal originating cancers being vastly more common. Acinar cell 
carcinomas (ACCs) are extremely rare comprising just 1-2% of pancreatic cancers. 
Histologically these tumors resemble PNETs and are identified by their high cellularity, acinar 
architecture, and lobular appearance. Similar to PNETs in terms of gross morphology, these 
tumors are also soft (Hackeng et al. 2016). The prognosis of patients with ACC is better than 
that of PDA with a 5-year survival of 25% (Wood and Klimstra 2014). 
Of the ductal cancers, pancreatic ductal adenocarcinoma (PDA) has the greatest 
incidence comprising >90% of all pancreatic cancers (Hackeng et al. 2016). Because PDA 
accounts for such a high percentage of pancreatic cancers, this term has become synonymous 
with pancreatic cancer. The gross morphology of PDA is striking, as these tumors are 
characteristically white in color and incredibly hard and dense. The histological organization of 
PDA is also unique consisting of two well-defined compartments, an invasive epithelium incased 
within a vast desmoplastic stroma. The borders of PDA are ill defined and epithelial infiltration 
past the main tumor occurs frequently (Vincent et al. 2011). While the epithelium consists of 
only one cell type, malignant ductal cells, the stroma is heterogeneous, containing pancreatic 
stellate cells, fibroblasts, endothelial cells, neuronal cells, immune cells, that are all structurally 
supported by extracellular matrix (ECM) components including collagen, hyaluronan, and 
fibrinogen (Olive 2015). The stroma is notably dense, hypovascular, and inflammatory 
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contributing to PDA’s unique microenvironment. One would think that this nutrient poor 
environment would stifle PDA growth, however PDA manages to flourish. PDA’s exceptional 
ability to adapt to a harsh microenvironment has been a subject of inquiry for decades and the 
exploitation of these survival mechanisms remains a critical area of therapeutics research.  
Pancreatic	  cancer	  microenvironment	  
 
The interaction between oncogenic epithelial cells and the surrounding stroma has been 
an area of deliberation. First thought to be simply a fibroinflammatory reaction to oncogenic 
lesions, the stroma is now thought to serve a role in both advancing and restraining PDA (Rhim 
et al. 2014). The complex crosstalk between the two compartments is credited with activating 
key signaling pathways, contributing to an immunosuppressive microenvironment, and 
progressing tumorigenesis (Tape et al. 2016; Rucki et al. 2017). However the stromal 
compartment has also been shown to restrain tumor progression (Rhim et al. 2014). Indeed 
inhibiting the Hh signaling pathway in a mouse model of PDA creates homogenous tumors 
lacking a stroma that are more vascular and aggressive than their hypovascular stroma-bearing 
counterparts (Rhim et al. 2014). While hypovascularity may serve to restrain tumor 
aggressiveness in certain contexts, this feature of the stroma also may lead to oncogenic 
metabolic reprogramming. Indeed the extreme hypoxia and nutrient deficiency resulting from the 
stromal microenvironment creates selective pressure for cells that can overcome these 
obstacles (DeBerardinis and Chandel 2016). Additionally low perfusion through blood 
vasculature, due to high interstitial fluid pressure, causes extensive complications in the 
therapeutics field due to decreased drug delivery and ensuing primary resistance to 
chemotherapeutics (Provenzano et al. 2012; Kultti et al. 2012; Olive et al. 2009). The PDA 
microenvironment is also highly immunosuppressive, creating complications for potential 
immunotherapies (Bazhin et al. 2013). Thus candidate therapeutics for PDA must first overcome 
this biological obstacle in addition to halting disease progression to claim efficacy.  
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Pancreatic	  cancer	  epidemiology	  
 
While the incidence and mortality associated with other common cancers, including lung, 
breast, colorectal and prostate, have been decreasing over the last several years, PDA 
continues to be a persistent threat, as both the incidence of PDA and deaths caused by the 
disease are on the rise (Vincent et al. 2011; Siegel, Miller, and Jemal 2017). Indeed, incidence 
and mortality are nearly identical in PDA as presentation of disease occurs at advanced stages 
and there are no truly effective treatments. PDA occurrence is higher in the developed world, 
increases with age, and is elevated in the African American population. Although PDA is 
multifactorial and the vast majority of cases are sporadic, the most significant known risk factors 
are a family history of pancreatic cancer (7-10% of cases), cigarette smoking (20% of cases), 
and chronic pancreatitis (4%) (Vincent et al. 2011; Ilic and Ilic 2016). Other risk factors include 
obesity, intake of red or processed meats, alcohol consumption, and diabetes (Ilic and Ilic 
2016).  
Clinical	  management	  of	  PDA	  
 
PDA remains one of the greatest challenges in oncology due to its lethality. One of the 
main reasons PDA is clinically problematic is because it is asymptomatic in early stages 
evading diagnosis until cancer is advanced and more difficult to treat. Tumors are usually only 
detectable after metastasis has occurred and the typical clinical symptoms: jaundice, weight 
loss, nausea, pain, cachexia, depression and gastric obstruction, arise from disease that has 
already invaded adjacent tissues (Ryan, Hong, and Bardeesy 2014b; Vincent et al. 2011).  
The main diagnostic test for PDA is Tri-phasic pancreatic-protocol CT, which is used to 
stage tumors and determine if patients are candidates for surgery (White et al. 2008). Clinical 
staging is based primarily on whether tumors can be removed with local resectable tumors at 
stage 0-II, borderline resectable and locally advanced unresectable tumors at stage III, and 
finally metastatic disease at stage IV (Wolfgang et al. 2013). The precarious location, close 
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proximity to the superior mesentery artery and vein, of most pancreatic tumors in addition to the 
high number of patients who present at stage IV is the reason for the low percentage of patients 
that qualify for surgery (15-20%) (Wong and Raman 2010). 
Tumor removal for pancreatic cancer is complex. The greatest advancement in PDA 
surgical removal was made at Columbia Presbyterian Hospital in 1935 when three surgeons 
attempted pancreaticoduodenectomies on three patients, two of whom survived for several 
months before succumbing to their disease (Are, Dhir, and Ravipati 2011). Coined the Whipple, 
after Allen Oldfather Whipple, this two-stage procedure includes the removal of the duodenum 
in addition to pancreatic tumor resection. The surgical resection of PDA is the single best 
curative treatment, however even after tumor removal patients only have better immediate 
survival rates and do not have an improved 5-year survival (Luberice et al. 2017).  
Neoadjuvant and adjuvant therapy with chemotherapeutics such as fluorouracil, 
irinotecan, oxaliplatin (FOLFIRINOX) and gemcitabine + Abraxane have had mixed results 
although in stage IV unresectable patients FOLFIRINOX or gemcitabine + Abraxane has been 
shown to extend survival in a small percentage of patients (Wolfgang et al. 2013; Ryan, Hong, 
and Bardeesy 2014a). Current standards of care in these cancers are the combination of 
FOLFIRINOX and gemcitabine + Abraxane, which are inefficient as these fail to influence 
survival in a majority of patients (Ryan, Hong, and Bardeesy 2014a).  
Precursors	  to	  PDA	  (PanINs,	  IPMNs,	  MCNs)	  
 
 PDA usually arises from neoplastic precursor lesions, pancreatic intraepithelial 
neoplasias (PanINs), which are microscopic, asymptomatic and may or may not progress to 
overt carcinoma. While PanINs are the most common precursor lesions, pancreatic cancers can 
also arise from intraductal papillary mucinous neoplasms (IPMNs) or mucinous cystic 
neoplasms (MCNs) (Hackeng et al. 2016). Of these precursor lesions PanINs have the greatest 
potential to develop into malignant invasive PDA.  PanINs are graded on a numerical system 
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based on histology, specifically the degree of cytological and architectural dysplasia, 
progressing from low grade PanINs, PanIN1, often present in older individuals, to high grade 




While early PanINs harbor some of the genetic mutations and epigenetic changes 
present in overt carcinoma, many are acquired as the lesion undergoes clonal expansion. The 
most common DNA mutations in PDA are activating mutations in the proto-oncogene KRAS 
(95%) and inactivating mutations in tumor suppressors p16/CDKN2A (95%), TP53 (75%), 
SMAD4 (50%), BRCA2 (5%) (Hruban, Goggins, and Kern 1999; Waddell et al. 2015; 
Rozenblum et al. 1997) (Introductory figure 1.1). This mutational repertoire first reported nearly 
20 years ago has persisted to date, apparent in multiple contemporary genome-wide analyses. 
Additionally PDA harbors gene amplifications, telomere shortening, and widespread 
chromosomal instability and losses (Hong et al. 2011). The earliest changes occurring even in 
nascent PanINs are mutations in Kras and telomere shortening, which are almost ubiquitous in 
PDA (Van Heek et al. 2002). Mutational changes in tumor suppressors occur later during clonal 
expansion and may not be present in all epithelial cells. Indeed it was recently revealed that 
while KRAS mutation is an early event in tumor initiation, apparent in 94% of high grade 
PanINs, p53 and SMAD4 mutations occur only in overt carcinoma (Hosoda et al. 2017). 
While the major mutational profile of pancreatic cancer is well known, this knowledge 
has not translated into new therapeutics, as oncogenic Kras is notoriously difficult to target. Kras 
has only been successfully targeted recently (June 2017) with AZD4785, a high-affinity 
antisense oligonucleotide inhibitor that just entered Phase 1 clinical trials (Ross et al. 2017). 
Efforts to re-express lost tumor suppressor function therapeutically have been fruitless to date. 
Whole genome sequencing of PDA has shown some promise, identifying candidate pathways 
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and master regulators to unveil potential therapeutic targets (Du et al. 2017). However the 
validity and benefit of inhibiting these target pathways remains to be seen.   
Kras	  mediated	  signaling	  pathways	  in	  PDA	  
 
 Signaling pathways in pancreatic cancer include those activated by oncogenic Kras 
(mutated in 95% of PDA): PI3K/AKT, MAPK/ERK, MYC as well as Hedgehog, and scavenging 
pathways autophagy and macropinocytosis. KRAS encodes small a GTPase that under normal 
conditions alternates between a GTP-bound active state and a GDP-bound inactive state (Shih 
et al. 1979; Gibbs et al. 1984). However mutations in this proto-oncogene in cancer, most 
frequently at the G12 residue, result in constitutive activity as they modify the interaction site of 
the GTPase. This modification alters the interaction between the GTPase and its activating 
proteins, GAPs, which regulate the switch to an inactive state (Hruban et al. 1993; Lemoine et 
al. 1992; Pylayeva-Gupta, Grabocka, and Bar-Sagi 2011). Kras acts at the membrane under 
influence of the epidermal growth factor receptor (EGFR). Upon EGF binding, Kras activity is 
initiated leading to downstream effects on both the PI3K/AKT and MAPK/ERK pathways. Both 
of these pathways are nutrient sensing pathways that function in the control of cell growth, 
proliferation, and survival. Because Kras acts as an intermediary between growth factor 
stimulated signaling at the membrane and downstream effector pathways, mutations in this 
proto-oncogene have vast consequences leading to increases in tumor proliferation, growth, 
and invasiveness, as well as decreased apoptosis (Perera and Bardeesy 2015).  
 Phosphoinositide 3-kinase (PI3K) signaling in PDA results mainly from oncogenic Kras 
activity and serves to drive a proliferative, anti-apoptotic, and pro-survival phenotype through 
downstream effector, mammalian target of rapamycin (mTOR) as well as through nuclear factor 
kB (NF-kB).  Indeed the effects of expression of a constitutively active PI3K in the pancreas are 
similar to those initiated by KrasG12D  in driving PDA progression (Eser et al. 2013). PI3K acts to 
convert phosphatiddlinositol (4,5)-biphosphate (PIP2) into second messenger 
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phosphatiddlinositol (3,4,5)-triphosphate (PIP3). PIP3 then activates AKT by binding to the 
pleckstrin homology (PH) domain. Finally the resulting kinase activity of AKT is responsible for 
the activation of proteins involved in cell growth, proliferation, and survival through 
phosphorylation (Cantley 2002). Aberrant signaling through this pathway in PDA may also be 
carried out through amplifications in AKT (Engelman, Luo, and Cantley 2006). Downstream of 
PI3K/AKT is activation of mTOR, a serine/threonine kinase, which exists in the mTORC1 
complex. This complex promotes protein translation though both S6 kinase and eIF4E 
mechanisms. mTOR inhibition results in decreased proliferation, cell cycle arrest, and reduced 
survival in PDA cells and in vivo, prompting clinical investigation (Morran et al. 2014; Lou et al. 
2014). PI3K effector NF-kB is also frequently activated in PD leading to changes in 
inflammation, proliferation, invasion and apoptosis (Prabhu et al. 2014). 
 The MAPK/ERK pathway is also activated by oncogenic Kras in PDA resulting in 
alterations in cellular responses including apoptosis, growth and differentiation (Campbell and 
Der 2004). MAPK/ERK was the first identified RAS effector pathway (Moodie et al. 1993; Vojtek, 
Hollenberg, and Cooper 1993; Zhang et al. 1993). The MAPK/ERK pathway is activated first 
through RAS, which stimulates kinase activity of serine/threonine kinase Raf. Raf then 
phosphorylates MEK, which in turn phosphorylates MAPK/ERK (Dhillon et al. 2007). Following 
activation MAPK/ERK has been shown to phosphorylate a vast number of substrates related to 
the progression of cancer (Dhillon et al. 2007). The MAPK/ERK and PI3K/AKT pathways 
phosphorylate and activate c-MYC, an important transcription factor in PDA. In fact, long-term 
MAPK/ERK inhibition in KRAS-mutant PDA in vitro and in xenograft studies induces growth 
suppression and is related with MYC degradation indicating MYC’s importance in PDA growth 
(Hayes et al. 2016).  
 Both the PI3K/AKT and MAPK/ERK pathways canonically are mediated by Kras through 
epidermal growth factor mediated signaling at the receptor. In fact EGFR is required for Kras 
induced tumorigenesis through the PI3K/AKT and MAPK/ERK (Ardito et al. 2012; Campbell et 
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al. 2007).  Aberrant activation of these nutrient-sensing pathways through mutation in the proto-
oncogene Kras is related to metabolic reprogramming in PDA. Indeed constitutive activity of the 
PI3K/AKT and MAPK/ERK pathways result in increased growth, proliferation and survival, 
improving the fitness of cancer cells. Both the scavenging pathways autophagy and 
macropinocytosis are also regulated by Kras and will be discussed in Chapter 3. 
Introduction	  to	  cancer	  metabolism	  
 
Tumor cells assume a transformed metabolic phenotype in order to maintain the 
uncontrolled growth and proliferation common to all cancers. This metabolic reprogramming 
allows for the creation of biomass, in the form of nucleotides, proteins, and lipids, to fuel cancer 
progression despite an often hypoxic and nutrient devoid microenvironment (Introductory Figure 
1.2). In the 1920s Otto Warburg first observed increased glucose uptake and aberrant glycolysis 
in tumor cells, the first of many hallmarks discovered distinguishing tumor cell metabolism from 
that of normal differentiated cells (Warburg 1956). This finding, now recognized as the 
foundation of the cancer metabolism field, occurred well before tumor suppressors and 
oncogenes were discovered in the 1970s and 1980s (DeBerardinis and Chandel 2016). Since 
then several features of tumor cells have become classified as hallmarks of altered cancer 
metabolism including excessive uptake and unorthodox utilization of glucose and amino acids, 
increased anabolic activity, and modification of nutrient sensing and scavenging pathways 
(DeBerardinis and Chandel 2016; Pavlova and Thompson 2016; Ward and Thompson 2012) 
(Introductory figure 1.3). Furthermore it has been established that the activation of oncogenes, 
loss of tumor suppressor activity, and stresses of the tumor microenvironment all support and 
foster the changes necessary for metabolic reprogramming (Ward and Thompson 2012). Once 
thought of as secondary reactions to tumorigenesis, these adjustments from normal cell 
metabolism are now thought to be adaptive, increasing the fitness of cancer cells and offering 
selective advantage in a challenging environment (DeBerardinis and Chandel 2016). Because 
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metabolic reprogramming occurs only in cancer cells, a crucial area of investigation in the field 
is the targeting of this process for therapeutic benefit.            
Important differences between tumor cells and normal cells include aberrant glucose 
metabolism, a shift to anabolic pathways, and elevated extracellular and intracellular 
scavenging (Perera and Bardeesy 2015). Oncogene activation, tumor suppressor loss and 
changes to the microenvironment all work in concert to drive metabolic reprograming. 
Particularly in the case of pancreatic cancer, mutant Kras driven changes have been shown to 
alter the metabolism of tumor cells resulting in increased uptake of glucose and amino acids, 
flux through anabolic pathways including de novo FA synthesis (dnFAS), and increased nutrient 
scavenging through macropinocytosis and autophagy (Introductory figure 1.3).  
Aberrant	  glucose	  metabolism	  
 
Termed the Warburg effect, aerobic glycolysis and excessive glucose uptake from the 
environment was the first recognized metabolic difference of tumor cells (WARBURG 1956). 
While normal quiescent cells undergo oxidative phosphorylation when oxygen is present, 
producing 36 ATP, and shift to glycolysis during hypoxia, producing only 2 ATP; tumor cells 
undergo glycolysis regardless of oxygen availability. Otto Warburg hypothesized that tumor cells 
shift their metabolism towards the energy inefficient glycolysis even in oxygen rich environments 
because they harbor mitochondrial defects forcing this unproductive phenotype (Weinhouse, 
Warburg, Burk, & Schade, 1956). We now know that aerobic glycolysis, rather than being an 
faulty method of obtaining ATP, is selected for in tumor cells because it allows for the 
unorthodox utilization of glycolytic intermediates to fuel excessive proliferation (Ward and 
Thompson 2012). Moreover it has been found that tumor cells’ mitochondria are intact and cells 
undergo oxidative phosphorylation, obtaining most of their ATP through this method. Thus 
tumor cells simultaneously participate in both glycolysis and oxidative phosphorylation. This 
uncoupling between glycolysis and oxidative phosphorylation is revealing of a more global 
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change in tumor metabolism blurring the separation between catabolic and anabolic states. 
Indeed the uncoupling of glycolysis from oxidative phosphorylation in tumor cells offers 
protection from feedback inhibition, as excessive ATP levels can halt glycolysis by inhibiting 
glycolytic enzymes (Scholnick, Lang, and Racker 1973). Aberrant glucose metabolism has been 
found in many tumors and cancer cells to the point where it has become an indisputable feature 
of cancer metabolism.  
PDA cells in particular exhibit increased glucose uptake and flux through the glycolytic 
pathway (Hu et al. 2012; Ying et al. 2012). This occurs through transcriptional upregulation of 
the glucose transporter GLUT1 as well as glycolytic enzymes HK1, HK2 and PFK1 (Ying et al. 
2012). Increased glycolytic flux generates pyruvate for the TCA cycle, a process whose 
intermediates are also utilized to power anabolic pathways, contributing to the creation of 
macromolecules. Additionally the creation of glycolytic intermediates is a shortcut in cancer 
through which cells can survive. Thus excessive glucose uptake and unconventional glycolysis 
ultimately serve as the groundwork for uncontrolled cellular growth and proliferation. 
Intermediates of the pathway support a shift to anabolic processes, the creation of 
macromolecules, and eventually the growth and division of tumor cells.  
Anabolism	  in	  cancer	  
 
Evidence for a metabolic shift towards anabolism is evident in the increased rates of 
protein, nucleotide, and FA synthesis seen in cancer cells. Shift to anabolism requires (1) 
glycolytic and TCA intermediates that heretically branch off to participate in different pathways 
(2) nutrients from extracellular uptake (3) constitutively active growth receptor pathways 
(Pavlova and Thompson 2016). Pancreatic cancers fulfill all of these requirements as they 
display increased uptake and utilization of glucose and glutamine, elevated scavenging through 
macropinocytosis, and Kras regulated constitutive activity through the PI3K/AKT and 
 12 
MAPK/ERK pathways. Anabolic pathways that are overactivated in PDA include the pentose 
phosphate pathway (PPP), de novo fatty acid synthesis, and protein synthesis.  
Nucleotide synthesis is increased in cancer to provide the precursors of DNA necessary 
for the production of a new daughter cell. Indeed, this vulnerability of cancer cells has been 
exploited therapeutically since the 1950s with genotoxic chemotherapies and radiation, which 
target the process. The PPP pathway utilizes products from increased glycolysis producing the 
ribose of DNA and is critical for genome duplication. Additionally this pathway generates 
NADPH, which acts as a reducing agent in other biosynthesis reactions. In particular dnFAS has 
the highest NADPH requirement at 14 NADPH molecules (Boyle 2005). Kras activation in PDA 
results in increased transcription of PPP enzymes, allowing for the creation of ribose 5-
phosphate, which is needed for DNA and RNA synthesis (Ying et al. 2012).  
Excessive protein synthesis in cancer requires abundant glutamine, essential amino 
acids, and is regulated by the mTOR pathway, which activates translation and ribosome 
biogenesis (Pavlova and Thompson 2016). The uptake of glutamine from the cellular 
environment was first observed by Harry Eagle, who found that HeLa cells uptake 10-100 times 
molar excess of glutamine when compared to other amino acids. Indeed the mTOR pathway, 
which is aberrantly activated in many cancers including PDA, stimulates cells to both uptake 
glutamine and converts glutamine to glutamate, providing growing cells with the building blocks 
for both protein and amino acid synthesis. Accordingly glutamine addiction through extracellular 
uptake is a well-known and common feature of PDA (Wise and Thompson 2010).  
Another anabolic pathway activated in tumor cells is the de novo synthesis of fatty acids 
(FAs), which are utilized for the creation of new cellular and organelle membranes, protection 
from ROS, increased cellular signaling through lipid rafts, and lipidation reactions. Indeed it has 
been shown that cancer cells utilize pyruvate, generated by excessive glycolysis, to participate 
in de novo fatty acid synthesis (dnFAS) (Introduction Figure 1.3)(Costello and Franklin 2005). 
Increased lipid synthesis is associated with tumorigenesis and is minimal in normal cells with 
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the exclusion of adipose tissue, liver, and mammary epithelium (Kusakabe et al. 2000). Cells 
require Acetyl-CoA from the TCA cycle as input, eventually synthesizing palmitate, the 
precursor for all fatty acids. Flux through this pathway is elevated in many cancers including 
breast, prostate, colon, and pancreatic (Alo et al. 2007; Francis P Kuhajda 2006). Additionally 
overexpression of the lipogenic enzymes involved in dnFAS reactions occurs in many cancers 
underscoring the pathways importance in cancer metabolism (Szutowicz, Kwiatkowski, and 
Angielski 1979). The relevance of this pathway in PDA will be discussed in Chapter 2.  
Of the three major anabolic pathways elevated in cancer, nucleotide, protein, and FA 
synthesis, FA synthesis has been the least targeted clinically. Indeed targeting nucleotide 
synthesis through nucleoside analogues, including gemcitabine, has been the standard of care 
for PDA for decades. Inhibitors of protein synthesis, including mTOR inhibitors, have been well 
explored, however none of these has been effective in PDA. Indeed it has been shown that 
inhibition of mTORC1 results in increased utilization of extracellular proteins, complicating 
inhibition of this pathway therapeutically (Palm et al. 2015). Targeting the dnFAS pathway in 
PDA is an exciting therapeutic strategy. Low flux through this pathway in normal cells implies 
that inhibition of the pathway will specifically target PDA cells. Targeting the pathway’s critical 
enzyme, FASN, will be discussed further in Chapter 2.  
Introduction	  to	  mouse	  models	  of	  cancer	  
 
Mouse models of cancer have been indispensible to the field of cancer biology allowing 
researchers to mimic the complexities and subtleties of human cancer in their quest to 
determine the underpinnings of the disease and further therapeutic discovery. Mouse models 
can be categorized a autochthonous and non-autochthonous (Le Magnen, Dutta, and Abate-
Shen 2016). Non-autochthonous models, or xenograft transplantation models, are models in 
which immuno-compromised mice are injected with human cancer cells in convenient sites. This 
model lacks a tumor fostering microenvironment, as cells are commonly not injected in the 
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tissue of origin and are not immuno-competent.(Le Magnen, Dutta, and Abate-Shen 2016). For 
pancreatic cancer, a multifaceted disease with a complex microenvironment, xenograft models 
have been of little utility, as they cannot reproduce the nuanced interaction between the 
oncogenic epithelium and the desmoplastic stroma nor the broad chemoresistance resulting 
from a hypovascular microenvironment (Olive et al. 2009).  
Alternatively in autochthonous models, tumors are generated in the tissue of origin, are 
immuno-competent, and are subject to a native microenvironment (Le Magnen, Dutta, and 
Abate-Shen 2016). These included three types: environmentally induced, spontaneous, and 
genetically engineered, with genetically engineered being the most employed model to date (Le 
Magnen, Dutta, and Abate-Shen 2016). While all three models have been crucial to our 
understanding of cancer, particularly the concepts of genetic predisposition, heritable mutations, 
multistage oncogenesis, and cancer proliferation; genetically engineered mouse models 
(GEMMs) have the benefit of accurately portraying human cancer genetic expression patterns 
mimicking common initial driving mutations as well as modeling the morphology, histopathology 
and clinical symptoms of cancer (Westphalen and Olive 2012).  
Environmentally induced models involve the introduction of carcinogens such as 
pollutants, chemicals, radiation, or viruses. Carcinogen induced mouse models were the first 
mouse models of cancer. These models were critical to the discovery of multistage 
carcinogenesis as well as instrumental in the effort to establish that smoking causes lung 
cancer, however they have been largely replaced by GEMMs because often they cannot 
accurately represent the precise genetic expression patterns and tissue type specificity of 
human cancers (Berenblum and Shubik 1947; Hecht et al. 1978; Pfeifer et al. 2002). 
Spontaneous models, such as mouse mammary tumor virus (MMTV), are not utilized frequently 
because it is unclear whether they mimic the human condition (Mant and Cason 2004).  
The first transgenic mice were generated in the 1980s by injecting cloned DNA into a 
single cell mouse embryo. These cloned genes were integrated into the mouse genome and 
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passed on to their progeny (Gordon et al. 1980). Oncogenes were discovered around this same 
time, cloned, and found to induce oncogenic transformation when expressed in cultured cells 
(Dominique Stehelin et al. 1976; D. Stehelin et al. 1976). The concert of two discoveries, 
oncogenes and transgenic mice, made possible the first genetically engineered mouse models 
(GEMMs) (Hanahan, Wagner, and Palmiter 2007).  
Contemporary GEMMs express oncogenes driven by tissue specific promoters 
generating tumors that arise in their tissue of origin and are subject to an immuno-competent 
microenvironment. GEMMs have the benefit of recapitulating the histopathology, molecular 
markers, genetic heterogeneity, immuno-competent microenvironment, and metastatic 
capabilities of human cancer (Le Magnen, Dutta, and Abate-Shen 2016). These models have 
proven essential over the years enabling a better understanding of disease progression, 
allowing for the discovery and validation of novel targets, testing efficacy of therapeutics and 
determining mechanisms of drug sensitivity and resistance. Other systems such as human 
cancer cell lines, 3D organoids and xenografts, while necessary for validation and directed 
mechanistic studies, lack the intricacy of an in vivo system. Thus genetically engineered models 
currently serve as vital multifaceted tools bridging research on the specific mutational drivers 
with therapeutics meant to treat these human-like cancers. 
The	  KC,	  KPC	  and	  KPfl/flC	  mouse	  models	  of	  pancreatic	  cancer	  
 
The first GEMM of pancreatic cancer that recapitulated pancreas tissue specific mutation 
in Kras was the K-rasLSL.G12DPdxCre (KC) mouse (Hingorani et al. 2003). This mouse develops 
early PanIns around 8 weeks, with a subset of mice developing PDA over the course of 2 years, 
revealing that Kras mutation alone is capable of causing PDA (Hingorani et al. 2003). After 
success with this mouse other common PDA driving mutations, including tumor suppressors 
cdkn2a and p53, were crossed into the KC model yielding mice that develop overt carcinoma 
more rapidly and with higher penetrance (Aguirre et al. 2003; Hingorani et al. 2005).   
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The model we utilize, the K-rasLSL.G12D/+; p53LSL.R172H/+; PdxCre/+, (KPC) model is a 
clinically predictive genetically engineered mouse model of pancreatic cancer (Hingorani et al. 
2005; Olive et al. 2009). These mice harbor targeted mutations in two of the most commonly 
mutated genes in human PDA, Kras (<90%) and p53 (75%) (Introductory Figure 1.4). KPC mice 
develop pancreatic tumors that are histologically similar to human tumors with a moderately 
differentiated ductal morphology and extensive stromal desmoplasia. They also develop 
metastases at the same sites as patients (liver, lungs, and peritoneum) and display similar co-
morbidities such as jaundice, ascites, and cachexia (Hingorani et al. 2005). Importantly, KPC 
tumors accurately recapitulate the broad chemoresistance that characterizes human PDA due 
to a chronic state of hypovascularity and hypoperfusion that limits drug delivery (Olive et al. 
2009). 
Similar to this model is the KPfl/flC model, in which p53 is homozygously deleted rather 
than heterozygously mutated. This model has the advantage of expedited tumor initiation and 
progression, making it ideal for short-term studies. KPfl/flC mice develop 3-6mm tumors at 
around one month and succumb to their disease around three months. These mice develop 
tumors that are generally histologically similar to those in the KPC model, although some tumors 
display a more mucinous phenotype.  
Tools	  for	  study	  mouse	  models	  
 
The use of GEMMs for preclinical cancer studies involves coordinated efforts with tumor 
monitoring, therapeutic intervention, and tumor analysis. In the Olive laboratory this this 
element, called the “Mouse Hospital", incorporates small animal imaging through high-resolution 
3D ultrasound to track tumor growth over time and a surgical suite with custom-designed 
instruments is available to carry out tumor biopsy surgeries (Introductory Figure 1.5) (S. A. 
Sastra and Olive 2013; S. a Sastra and Olive 2014). Combined with expertise in drug 
administration, tissue sampling, histopathology, pharmacology, the Mouse Hospital unit 
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Chapter	  2	  –	  FASN	  and	  lipogenesis	  in	  cancer	  
FASN is responsible for catalyzing the reductive synthesis of palmitate from acetyl-CoA, 
malonyl-CoA, and NADPH, as part of the de novo FA synthesis pathway (Francis P Kuhajda 
2006). This enzymatic step is rate limiting and its product, palmitate, is the precursor to all long-
chain FAs. As the only mammalian protein capable of long-chain FA synthesis, FASN is critical 
for supporting the elevated proliferation rates of cancer cells, particularly through the synthesis 
of the phospholipid components of biological membranes. In the 1950s, in vivo 14C-glucose 
labeling experiments showed in tumor models that all esterified FAs (precursors of 
phospholipids) were derived from de novo synthesis (Medes, Thomas, and Weinhouse 1953). 
Furthermore these FAs account for more than 93% of total tumor triglycerides (Szutowicz, 
Kwiatkowski, and Angielski 1979). Contemporary work continues to cement the role of FASN in 
cancer biology. Indeed, FASN is overexpressed in many cancers, including breast, prostate, 
colon and pancreatic, where it has been shown to elevate cancer cell growth and survival (Long 
et al. 2014). Crosstalk between FASN and oncogenic signaling pathways, including Kras, 
PI3K/AKT, and MAKP/ERK, has also indicated that this enzyme is crucial in the process of 
metabolic rewiring (Menendez and Lupu 2007). In PDA upregulation of FASN is correlated with 
poor prognosis, poor differentiation and advanced tumor grade (Walter et al. 2009; Alo et al. 
2007). Furthermore Kras-driven PDA cells in vitro have been shown to be highly dependent on 
de novo FA synthesis and thus FASN function (Li and Cheng 2014). Given the lack of FASN 
expression in most normal tissues, this protein has become an important target for cancer and 
thus is an ideal therapeutic target for PDA. 
FASN	  introduction	  
 
 The FASN homodimer is a structurally complex multifunctional enzyme consisting of 270 
KDa polypeptides that each harbor the seven catalytic domains solely responsible for 
mammalian de novo fatty acid synthesis (Maier 2006; Asturias et al. 2005; Chirala and Wakil 
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2004). FASN participates in a sequential series of decarboxylative condensation reactions, 
during which the elongating FA carbon chain is shuttled to each active site escorted by acyl 
carrier protein (ACP) (Philip W Majerus, Alberts, and Vagelos 1965; P. W. Majerus, Alberts, and 
Vagelos 1965). The terminal active site is the thioesterase unit where free palmitate, FASN’s 
primary product and the precursor to all de novo FAs, is released (Smith, Witkowski, and Joshi 
2003; Menendez and Lupu 2007). FASN is the rate-limiting enzyme of the de novo FA synthesis 
pathway. This protein has very low expression in normal tissues, where most FAs are obtained 
through diet, with the exception of adipocytes, liver, mammary glands during lactation, and fetal 
tissues (Wagle et al. 1999; Weiss et al. 1986; Kusakabe et al. 2000). Conversely tumors 
express high levels of FASN and undergo elevated de novo FA synthesis in order to generate 
lipid and organelle membranes for rapidly proliferating cells. Accordingly FASN has become a 
target for anticancer therapeutics most recently prompting the development of novel agents 
targeting the thioesterase domain which have shown promise in studies and clinically (M. et al. 
2015; Jones and Infante 2015) .  
FASN	  expression	  in	  cancer	  	  
 
While the FASN protein had been identified and shown to be a single multifunctional 
homodimeric enzyme in the 1970s, it was not until the 1980s, when hormone positive breast 
and prostate cancer cells were shown to increase expression of FASN with progestin and 
androgen treatment respectively, that this enzyme became associated with cancer biology 
(Chalbos et al. 1987; Chambon et al. 1989). Later in the 1990s Kuhajda et al uncovered 
elevated FASN expression in breast cancer samples of patients with poor prognosis implicating 
FASN’s role in cancer progression and garnering interest in therapeutic inhibition of the enzyme 
(Smith, Witkowski, and Joshi 2003; F P Kuhajda, Piantadosi, and Pasternack 1989; F. P. 
Kuhajda et al. 1994). After the initial discovery of FASN in breast cancer tumors, it has been 
shown that FASN overexpression occurs in multiple tumor types, including pancreatic, prostate, 
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colon, lung, ovary among others, and is even present in the serum of patients harboring these 
tumors (Walter et al. 2009; Long et al. 2014; Menendez and Lupu 2007). Additionally it has 
been shown that many of these cancers possess elevated FASN both at the protein and mRNA 
levels where expression is correlated with poor outcome (Menendez and Lupu 2007; Long et al. 
2014; M. et al. 2015). Furthermore FASN inhibition has been shown cause cell cycle arrest at 
G1/S phase and eventual apoptosis in several types of cancer both in vitro and in vivo indicating 
that this protein is important for proliferation and cell survival (Pizer, Wood, et al. 1996; Pizer, 
Jackisch, et al. 1996; W. Zhou et al. 2003; Kridel et al. 2004). 
FASN expression and lipogenesis in normal cells acts to store energy in the form of 
triacylglycerols that can be released through beta-oxidation. Conversely, expression of FASN in 
cancer serves to create lipid membrane components, particularly phospholipids (Sul and Wang 
1998; F. P. Kuhajda et al. 1994). Indeed it has been shown that in normal cells increased 
malonyl-CoA levels that occur during lipogenesis can inhibit enzyme carnitine 
palmitoyltransferase-1 (CPT-1), preventing their utility in fatty acid oxidation and positioning 
them for storage (McGarry and Brown 1997). Normally in conditions of starvation FASN 
expression is reduced along corresponding with lower malonyl-CoA. Alternatively in cancer, 
oncogene activation driving alterations in nutrient signaling pathways and aberrant glycolysis 
induce a state of constitutive lipogenesis (Menendez and Lupu 2007). As the primary enzyme 
responsible for de novo FA synthesis FASN is coordinately overexpressed in cancer.  
FASN	  Signaling	  
 
Regulation of FASN occurs through receptor tyrosine kinases, such as epidermal growth 
factor receptor (EGFR). After ligand binding, these growth factor receptors undergo trans-
autophosphorylation of their C-terminal tyrosine residues. These autophosphorylation events 
create a docking area where RTKs can activate PI3K directly or through adaptor proteins 
(Swinnen, Heemers, et al. 2000). One such adaptor protein is GRB2, which activates PI3K 
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signaling through RAS. Accordingly in RAS-driven cancers, the PI3K/AKT pathway is aberrantly 
overactivated. PI3K/AKT pathway activation ultimately regulates expression of transcription 
factor sterol regulatory element binding protein 1, SREBP1, which binds to the endogenous 
FASN promoter. SREBP1 can also be activated by the MAPK/ERK pathway, which is similarly 
overactivated in cancer through oncogenic Ras, the pathway’s upstream activator. In normal 
cells SREBP1 mediates nutrients and hormone signals stimulating FASN expression 
accordingly (Rawson 2003; Eberlé et al. 2004). In cancer, growth factor receptor pathways are 
deregulated through oncogenic RAS and activating mutations in pathway members, such as 
AKT, promoting FASN overexpression through SREBP1. Inhibitors of both the PI3K/AKT and 
MAPK/ERK have been shown to downregulate FASN expression through SREBP1 (Swinnen et 
al. 1997; Yang et al. 2003). Additionally multiple studies have shown correlations between 
FASN expression and activation of the PI3K/AKT pathway, mainly in prostate cancer cells, 
indicating that oncogenic PI3K/AKT activity leads to FASN overexpression (Van de Sande et al. 
2005, 2002; Y Yang 2002). It is also notable that expression of PTEN, a tumor suppressor that 
negatively regulates the PI3K/AKT pathway, is inversely related to FASN expression 
(Bandyopadhyay et al. 2005). Notably the expression of FASN through SREBP1 occurs 
simultaneously with increases in expression of other lipogenic enzymes, indicating that SREBP1 
is a general regulator of lipogenesis (Swinnen, Ulrix, et al. 1997; Swinnen, Vanderhoydonc, et 
al. 2000). While FASN is canonically regulated through growth factor mediated signaling, an 
alternate post-translational mechanism of FASN regulation, shown in prostate cancer, is through 
ubiquitin specific protease, USP2a, which stabilizes FASN through the removal of ubiquitin 
(Graner et al. 2004; Priolo et al. 2006).  
FASN	  in	  PDA	  
 
There is increasing evidence that FASN overexpression is a cancer survival mechanism 
sustaining cell proliferation while lipids are scarce. This function is especially relevant in PDA, a 
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cancer whose defining feature is nutrient deficiency, resulting from the development of a 
hypovascular stroma (Olive et al. 2009).  Indeed, in a recent metabolomics study it was found 
that most lipid metabolites are depleted in PDA when compared to surrounding tissue (Jurre J. 
Kamphorst et al. 2015). FASN expression is increased in patients with PDA in tumors and 
serum. In a screen of 144 patients with PDA or precursor lesions, ~90% showed FASN protein 
overexpression relative to pancreatitis and normal controls (Walter et al. 2009). Elevated serum 
FASN levels are also seen in PDA patients and interestingly these levels fall rapidly after 
surgical resection, indicating the tumor itself may be responsible for aberrant FASN expression 
(Walter et al. 2009). Elevated FASN levels are associated with high tumor grade and lower 
differentiation status in PDA, supporting a role for FASN in tumor progression (Witkiewicz et al. 
2008).  
Clinically FASN expression is correlated with poor prognosis in PDA (Alo et al. 2007; 
Witkiewicz et al. 2008). Likewise expression of SREBP1, a transcription factor controlling FASN 
expression and oncogenic lipogenesis, also correlates with poor survival clinically (S. Y. Jung et 
al. 2012; Sun et al. 2015). It has been shown in vitro and in vivo that FASN drives resistance to 
radiation and to gemcitabine (a common pancreatic cancer chemotherapy), indicating that dual 
treatment with FASN inhibitors should be explored (Youyun Yang et al. 2011; Tadros et al. 
2017).  
In vitro studies have shown that PDA cell lines exhibit high rates of de novo FA synthesis 
(dnFAS) compared to immortalized primary pancreatic ductal cells and furthermore that 
knockdown of FASN using RNA silencing methods reduces cell proliferation and increases 
apoptosis (Li and Cheng 2014; De Schrijver et al. 2003). These findings indicate that aberrant 
flux through the dnFAS is a critical feature of PDA necessitating FASN overexpression. Indeed 
pantothenate, a critical precursor to coenzyme A (CoA) was found to be depleted in PDA tissue 
in a recent metabolomics study, suggesting that CoA stocks are in high demand and that there 
is increased flux through the de novo FA synthesis (Jurre J. Kamphorst et al. 2015). Pancreatic 
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cancer’s classic hypovascularity creates a hypoxic environment. In both in vitro and in vivo 
models of breast cancer hypoxia has been shown to upregulate FASN, suggesting a protective 
role of dnFAS in cancer (Furuta et al. 2008). Additionally Kras-driven cancers harbor high levels 
of ROS, which can induce PanIN formation and participate in aberrant signaling (Martinez-
Useros et al. 2017; Liou et al. 2016). It has been shown that lipids created through dnFAS may 
be protective against ROS (Rysman et al. 2010; Bailey et al. 2015). Taken together this 
evidence suggests that FASN overexpression contributes to a critical lipogenic phenotype in 
PDA and inhibition of the FASN enzyme should be explored further as a therapeutic target.  
FASN	  inhibition	  in	  cancer	  
 
As the only mammalian protein capable of long-chain FA synthesis, FASN is critical for 
supporting the elevated proliferation rates of cancer cells, particularly through the synthesis of 
the phospholipid components of biological membranes. FASN upregulation correlates with poor 
prognosis in multiple cancers, including pancreatic, suggesting that tumors may generally rely 
on de novo fatty acid synthesis (Menendez and Lupu 2007). Inhibition of this pathway has 
recently been a subject of focus in the cancer therapeutics field and has been accomplished 
using cerulenin, C75, Orlistat, TVB-2640 and IPI-9119.  
Cerulenin, a natural fungal antibiotic isolated from Cephalosporium caerulens, was the 
first of these agents utilized in cancer studies as a FASN inhibitor (Vance et al. 1972; Pizer, 
Wood, et al. 1996). C75, whose synthesis is based on cerulenin’s mechanism of action similarly 
targets the βketoacyl domain of FASN and has been utilized in several cancer studies as well, 
causing effects on cell cycle and inducing apoptosis (F P Kuhajda 2000; Gao et al. 2006; W. 
Zhou et al. 2003; Funabashi et al. 1989)(Pizer et al. 2000)(Wang et al. 2005). However off-
target effects and the irreversibility of the agents have obviated Cerulenin and C75 from clinical 
therapeutic adaptation (Angeles and Hudkins 2016; Cheng et al. 2014). Indeed, C75 has also 
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been found to reduce food intake mice, preventing the animals from obtaining dietary lipids in 
addition to de novo FAs (Loftus 2000). 
Orlistat, an agent used to treat obesity, was found to harbor FASN inhibitory activity at 
the thioesterase domain and has since been utilized in several cancer studies restraining 
proliferation in vitro and inducing apoptosis in vivo (Kridel et al. 2004). Indeed it was through the 
crystallization of Orlistat bound FASN, at the thioesterase domain, that this domain was first 
structurally elucidated (Pemble et al. 2007). Orlistat also functions as a pancreatic and gastric 
lipase inhibitor preventing FA absorption by the GI, hence the drugs utility in treating obesity. 
However this attribute may be undesirable in a cancer therapeutic, as it would target normal 
cells reliant on dietary lipids, in addition to cancer cells. While Orlistat has been utilized both in 
vitro and in vivo where it reduces proliferation, the agent has largely been abandoned clinically 
due to pharmacological limitations including, bioavailability and water solubility (Kridel et al. 
2004; Mullen and Yet 2015).   
Compared to these commonly utilized FASN inhibitors, TVB-2640, recently developed 
by 3V-biosciences, has the best performance and is the first to be used in a clinical trial. This 
agent is currently in phase II clinical trials for high grade astrocytoma and HER2 positive breast 
cancer, after performing favorably in phase I solid tumor pharmacokinetic trials 
(www.clinicaltrails.gov; M. et al. 2015). Importantly work with TVB-2640 has indicated the 
potential clinical relevancy of FASN inhibition. 
In the work presented here we will utilize a FASN inhibitor IPI-9119 which was 
developed by Infinity pharmaceuticals and has been shown to potently inhibit FASN activity in 
vivo. Unlike TVB-2640, this agent is an irreversible inhibitor targeting the thioesterase domain of 
FASN, similar to Orlistat. IPI-9119 treatment inhibits FASN activity in colon cancer cells in vitro 
and in a corresponding in vivo xenograft study for up to 12 hours (unpublished data from Infinity 
Pharmaceuticals). Compared to cerulenin, c75, and Orlistat, IPI-9119 has high bioavailability 
and can be administered orally making this agent ideal for therapeutic development. One of the 
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challenges in treating pancreatic cancer is that tumors are notoriously dense and hypovascular, 
features that impede drug delivery to the tumor parenchyma (Olive et al. 2009). The biophysical 
barrier to drug delivery may be overcome through the use of agents with several properties: a) a 
long circulating half-life, enables to drug to achieve equilibrium concentrations in tumor tissues; 
b) a high therapeutic index (range of concentrations between efficacy and toxicity); and a low 
koff, such that even the reduced supply of agent to the tumor can eventually produce efficacious 
















Chapter	  3	  –	  Lipid	  scavenging	  in	  cancer	  	  
 The increased demand for nutrients to fuel excessive proliferation in cancer necessitates 
unorthodox methods of acquisition including scavenging from both intracellular and extracellular 
environments. It is established that many cancers, including PDA, display increased autophagy, 
a recycling process that breakdowns intracellular structures by packing them into vesicles called 
autophagosomes (Jiang, Overholtzer, and Thompson 2015; Ladoire et al. 2012). While cancer 
cells display increased uptake of glucose and glutamine through membrane transporters, these 
cells also can actively internalize amino acids, proteins, lipids and other nutrients from the 
external environment through macropinocytosis, a type of endocytosis allowing for the 
engulfment of large areas of extracellular space (Commisso et al. 2013; Jurre J. Kamphorst et 
al. 2015; J. J. Kamphorst et al. 2013). Aberrant activity through the autophagy and 
macropinocytosis pathways allows cancer cells to obtain extra nutrients to sustain growth and 
survival in a harsh environment. Importantly recent work has shown that both pathways are 
overactivated in Ras-driven cancers, including PDA. Autophagy and macropinocytosis are 
catabolic processes that converge upon the lysosomal degradation pathway, culminating in the 
digestion and recycling of cargo. Recent evidence has shown that targeting these pathways 
may be clinically beneficial, especially in the context of other therapeutics. Treatment with 
lysosomal inhibitor, CQ, has been shown to sensitize cancer cells to chemotherapy and is 
currently in a number of clinical trials as monotherapy or in combination with various 
chemotherapies and inhibitors.  
Autophagy	  introduction	  
 
 Autophagy, derived from the Greek words for “self-eating,” is a homeostatic recycling 
pathway essential for proper maintenance of all eukaryotic cells (Kawabata and Yoshimori 
2016). The term autophagy was first coined in the 1950s by Christian de Duve, who won the 
1974 Nobel Prize in Physiology or Medicine for the discovery of lysosomes, after witnessing the 
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degradation of cytoplasmic contents including mitochondria, ribosomes, Golgi and ER 
components through the lysosomal pathway (Deter, Baudhuin, and De Duve 1967; Levine and 
Klionsky 2017). His characterization of the process served to distinguish the self-degradation of 
autophagy from the degradation of extracellular components. This pathway is highly conserved 
and operates to degrade and recycle intracellular components, including organelles, pathogens, 
lipids and proteins (Nakamura and Yoshimori 2017). While flux through the pathway is relatively 
low in normal cells during basal conditions, autophagy is increased as a survival response to 
starvation, pathogen invasion, protein accumulation, and organelle damage (Nakamura and 
Yoshimori 2017). Indeed autophagy acts as a cell survival mechanism even in cancer, where it 
sustains cells in nutrient replete and hypoxic conditions.  
Autophagosome	  formation	  and	  degradation	   	  
 
 The process of autophagy begins in the cytoplasm with a small sac that eventually 
elongates to form the cup-shaped nascent autophagosome (also called phagophore). Signaling 
through Atg (autophagy-related genes) proteins and LC3B (mammalian homologue of yeast 
ATG8) among others is responsible for cargo selection, elongation of the surrounding 
membrane, and closure to form a double membranous mature autophagosome. Degradation 
occurs through the fusion of the mature autophagosome with a lysosome, now termed 
autolysosome. The terminal step is part of the lysosomal degradation pathway in which cargo 
contents are broken down and released into the cytoplasm (Introductory Figure 1.6).    
The core machinery of controlling autophagosome formation is regulated by the ATG 
genes, first identified and characterized in yeast by the screening autophagy deficient mutants 
(Tsukada and Ohsumi 1993; Harding et al. 1995; Thumm et al. 1994). Yoshinori Ohsumi 
received the 2016 Nobel Price in Physiology or Medicine for this seminal work, which reveals 
the molecular mechanisms of the autophagy pathway, particularly the functions of ATG proteins 
in the progression of autophagosome formation and elongation (Harnett et al. 2017). While 
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autophagy was first thought to be a solely nonselective system for cellular self-degradation, it is 
now known that specific proteins bind to cargo selectively targeting it for degradation. These 
selective processes include mitophagy (autophagy of mitochondria) and lipophagy (autophagy 
of lipids) have been shown to be involved in normal homeostatic autophagy functions as well as 
aberrant processes related to cancer. 
The ULK1 kinase complex drives autophagy initiation dependent on its phosphorylation 
status. This complex acts as a molecular switch controlled by input from nutrient sensing 
pathway complex mTORC1, which assesses both growth factors and amino acid availability 
(Jiang, Overholtzer, and Thompson 2015). Under low nutrient conditions mTORC1 is inactivated 
and ULK1 is hypo-phosphorylated resulting in increased autophagic flux (Hara et al. 2008; 
Ganley et al. 2009; C. H. Jung et al. 2009). After activation of autophagy, ULK1 has been shown 
to activate a second complex, VPS34 (a class III PI3K), through phosphorylation of beclin 1 
(Itakura and Mizushima 2010; Nazarko and Zhong 2013). This complex then activates the ATG5 
complex, composed of ATG5-ATG12-ATG16, which are conjugated to a autophagy specific 
ubiquitin-like process (Itakura and Mizushima 2010). The ATG5 complex next activates the 
conjugation machinery of LC3B (ATG8 in yeast), which also involves Atg7 and Atg3. Atg4 is the 
only protease Atg and is responsible for processing LC3B, exposing its C-terminus. This step 
allows for the cascade of events leading to the lipidation of LC3B-I (cytosolic) to LC3B-II 
(membranous) that includes the covalent addition of phosphatidylethanolamine (PE) to LC3B as 
well as a series of ubiquitin-like conjugation reactions. Atg4 is also responsible for de-lipidation 
of LC3B, leading to the proteins eventual recycling. Inhibition of Atg4 activity accordingly inhibits 
autophagosome formation resulting in accumulation of LC3B-I (Nakatogawa and Ohsumi 2013).  
The unique protease activity of Atg4 makes it an attractive target and many functional 
autophagy studies utilize knockdowns of this protein. Indeed we utilize a dominant negative 
mutant ATG4 cell line to study genetic autophagy ablation in mouse PDA cell lines. The final 
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step of this process is the fusion with lysosome and eventual degradation of cargo through the 
lysosomal pathway. 
Autophagy	  in	  cancer	  
 
In many cancers the autophagy pathway is overactivated and cells self-catabolize 
cytosolic components to provide the macromolecular building blocks needed for augmented 
cellular growth and proliferation. Autophagy, a recycling homeostatic process, is normally 
activated during times of cellular stress. The cancer microenvironment is similar to instances of 
cellular stress exposing cells to nutrient deficiency, hypoxia and ROS. The role of autophagy in 
cancer is complex and has been shown to both support and restrain tumorigenesis. Autophagy 
can restrain initiation of tumorigenesis through the recycling of damaged organelles and protein 
aggregates therefore limiting the carcinogenic effects of tissue damage, inflammation and 
genome instability (Guo, Xia, and White 2013; Kimmelman and White 2017). On the other hand 
after tumorigenesis occurs, autophagy acts as a cancer survival mechanism, supporting 
tumorigenesis by providing recycled nutrients (Guo, Xia, and White 2013; Kimmelman and 
White 2017). Specific deletion of autophagy protein beclin-1 can initiate tumorigenesis indicating 
that autophagy is a tumor suppressive mechanism, at least in early stages (Yue et al. 2003; Qu 
et al. 2003). Autophagy has also been shown to initiate a type of programmed cell death that 
could limit cancer growth (Bursch 2001). Alternatively in the context of established cancer, 
autophagy is a critical driver of tumorigenesis. Specifically in the case of RAS-driven cancers 
autophagy has been shown to be crucial following carcinogenesis. RAS-driven cancers, non-
small cell lung carcinoma (NSCLC) and PDA, both display attenuated tumor growth and 




Autophagy	  in	  RAS-­‐driven	  cancer	  
 
Basally autophagy regulates homeostasis between biosynthesis and catabolic pathways 
by breaking down and recycling components resulting protein and organelle turnover. Levels of 
autophagy are only elevated during cellular stress such as nutrient stress, hypoxia, or oxidative 
stress. The induction of autophagy in the context of cancer can be regulated by the activation of 
oncogenes or loss of tumor suppressors. RAS-driven cancer display elevated flux through the 
autophagy pathway. This is thought to be due to their increased dependence on nutrients such 
as glutamine, glucose, and lipids as well as their required maintenance of mitochondrial function 
to prevent accumulation of ROS (Guo, Xia, and White 2013). Indeed autophagy has been found 
to facilitate glycolysis, maintain oxidative metabolism, and support lipid homeostasis all in the 
context of RAS transformation (Lock et al. 2011; Guo et al. 2011, 2013). Cells transformed by 
oncogenic KRAS accumulate defective mitochondria, which in the absence of autophagy (Atg5 
or Atg7 deletion), cause cancer cell death (Guo et al. 2011). Autophagy inhibition by Atg7 
deficiency can also reduce fatty acid oxidation, altering the make-up of lipid pools (Guo et al. 
2013).  
Autophagy has also been shown to be a critical factor in tumor progression. In a KRAS 
driven GEMM of PDA as well as in human PDA cell lines autophagy inhibition by Atg7 deletion 
and CQ treatment restrains tumor development (S. Yang et al. 2011). However, the effect of 
autophagy on RAS-driven cancers has been found to be dependent TP53 status. Many lines of 
evidence indicate that autophagy in RAS-driven cancer is highly dependent on p53 status and 
vice versa. Kras-driven GEMMs of lung cancer are dependent on eventual acquisition of TP53 
mutations to progress to overt carcinoma. The genetic ablation of autophagy through Atg7 
deletion however induces p53 activity causing cell cycle arrest consequently preventing TP53 
mutations (Guo et al. 2013). This evidence suggests that autophagy can regulate p53 function. 
In a GEMM of PDA that is KRAS mutated and TP53 null, the deletion of ATG7, ATG5, and 
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treatment with hydroxychloroquine (HCQ) all caused an accelerated cancer phenotype, a result 
that contradicted earlier findings in GEMMs of PDA (Rosenfeldt et al. 2013). Further work on 
this topic by the Kimmelman group revealed that in the context of mutant KRAS, TP53 deletion 
and TP53 loss of heterozygosity (LOH) regulate tumorigenesis in opposite ways during 
autophagy inhibition. TP53 deletion in this context causes cancer progression while TP53 LOH 
attenuates progression. Thus there is significant evidence that autophagy’s role in cancer is 
dependent on a number of factors including the stage of cancer progression, whether the 
cancer is RAS-driven, and the status of TP53 in both these contexts.   
 It is relevant that both these models are developmental rather than therapeutic. In this 
study we utilize the KPfl/flC model, a TP53 deletion model with mutant KRAS, to study the 
effects of dual scavenging and FASN inhibition. As opposed to developmental models that 
contain Atg7/Atg5 embryonic pancreas specific deletions or models in which CQ is administered 
to mice in early stages, we monitor tumor progression by palpation and only enroll mice into 
studies after a tumor is detected. This occurs at about 6 weeks, which is later than the reported 
start of treatment in previous studies at 3-4 weeks. This method verifies that studies are 
exploring the effect of agents after tumor establishment, rather than pre-therapeutically.  
Autophagy	  in	  pancreatic	  cancer	  
 
 Increased activity through the autophagy pathway is a later event in the progression of 
PDA, occurring after oncogenic KRAS transformation around the PanIN3 stage (Perera and 
Bardeesy 2015). Aberrantly high levels of autophagy are seen in human PDA and furthermore 
this pathway has been shown to be necessary for tumor progression in the KPC PDA mouse 
model (S. Yang et al. 2011). Studies inhibiting autophagy using RNA silencing methods or 
lysosomal inhibitor chloroquine (CQ) in PDA cell lines demonstrate attenuated growth (S. Yang 
et al. 2011). PDA’s dependence on autophagy is not surprising as this tumor type is highly 
addicted to glutamine, deficient in amino acids and lipids, and hypoxic. In a non-small cell lung 
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carcinoma (NSCLC) GEMM driven by KRAS and TP53 mutations, autophagy has been shown 
to sustain cells during glutamine depletion, protect from hypoxia, and maintain lipid homeostasis 
(Guo et al. 2013; Lock et al. 2011). Due to PDA’s similarities with NSCLC, including KRAS and 
TP53 mutations, we suspect that autophagy may also sustain PDA in these ways. Importantly 
treatment with HCQ in the KPC mouse model resulted in reduced tumor growth and increased 
survival, indicating that HCQ is clinically relevant therapeutic (S. Yang et al. 2011). Indeed this 
agent is currently in Phase II clinical trials for PDA (www.clinicaltrials.gov).  
Macropinocytosis	  introduction	  
 
Macropinocytosis is a non-selective endocytotic pathway through which cells internalize 
large areas of extra-cellular space. Actin cytoskeletal remodeling at the cell membrane, induced 
by growth factor receptor signaling, leads to membrane ruffling. Eventually lamellipodia form at 
the cell surface, some of which double back and fuse with the cell membrane. The resulting 
double membraned vesicles from these fusion events are termed macropinosomes. These 
structures ultimately combine with lysosomes and their contents are degraded and released into 
the cytoplasm. Macropinocytosis is unique, compared to other endocytotic pathways in that it 
has no specific markers, cargo selection process, or direct regulatory activation (Kerr and 
Teasdale 2009). Following RTK signaling, macropinocytosis is dependent on the mechanisms 
controlling actin polymerization at the membrane. GTPases, Rho, Cdc42 and Rac coordinate 
with PIP2, which after activation by WASp/Scar, forms a complex with Arp2/3 to assemble a 
new actin monomer onto a pre-existing actin filament (Stradal et al. 2004; Kerr and Teasdale 
2009). How membrane ruffling causes the formation of membrane extensions and eventually 
macropinosomes is unknown. There is evidence that the closure of macropinosomes is 
dependent of PI3K activity and in vitro studies show that PI3K inhibitors prevent 
macropinocytosis but not membrane ruffling (Amyere et al. 2000; Araki, Johnson, and Swanson 
1996; Araki et al. 2007). Macropinocytosis occurs basally in many normal cell types where it had 
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roles in cell motility, immune system antigen presentation, and response to pathogen infection 
(Carpentier et al. 1991; Norbury et al. 1995; Mercer and Helenius 2008). More recently 
macropinocytosis has been found to act as a nutrient supply mechanism in Ras driven cancers 
(Commisso et al. 2013).  
Macropinocytosis	  in	  Ras-­‐driven	  cancer	  
 
Macropinocytosis in malignant cells was first observed in the 1930s by Warren H. Lewis 
who described “wavy ruffle pseudopodia” that were capable of engulfing cell culture media 
components, including dead cells (Lewis 1937). Since then macropinocytosis has been found in 
several cancer types where it can be regulated by RTK activation or oncogenes, including Ras 
(West, Bretscher, and Watts 1989; Jurre J. Kamphorst et al. 2015; Araki et al. 2007). Ras-driven 
macropinocytosis was first observed in the 1980s, in oncogenic Hras injected rat fibroblasts 
(Bar-Sagi and Feramisco 1986). Nearly 15 years later, when the subject was revisited, 
macropinocytosis was found to rely on PI3K activity in Kras-transformed rat fibroblasts (Amyere 
et al. 2000).  
Most recently multiple studies have identified Ras-driven cancers as being particularly 
dependent on macropinocytosis as a nutrient supply route. It bas been shown that oncogenic 
Ras drives the macropinocytosis of amino acids, proteins, and possibly unsaturated lipids 
(Commisso et al. 2013; J. J. Kamphorst et al. 2013; Jurre J. Kamphorst et al. 2015; Bar-Sagi 
and Feramisco 1986). Both HRAS and KRAS mutations in bladder and pancreatic cancer cells 
respectively display increased macropinocytosis compared with non-mutated controls, further 
implicating the role of macropinocytosis in Ras-driven cancers (Commisso et al. 2013).  
Macropinocytosis	  in	  pancreatic	  cancer	  
 
 Pancreatic cancers are known for their extreme microenvironment, harboring nutrient 
deficiency, hypoxia, and ROS. A recent study displayed that PDA tumor tissue, when compared 
to adjacent non-carcinoma tissue, is undersupplied in glucose, glycolytic intermediates, and 
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amino acids: glutamine and serine (Jurre J. Kamphorst et al. 2015). To accommodate for these 
insufficiencies both Kras-driven PDA cultured cells and human tumor slice samples scavenge 
from the extracellular environment. PDA cultured cells internalize protein albumin providing 
amino acids for cellular processes and human ex-vivo tumor slices actively take up labeled 
dextran (Jurre J. Kamphorst et al. 2015). Furthermore in a GEMM of PDA (P48-cre: lsl-
KrasG12D;TRP53-/+) macropinocytosis was observed in epithelial cells of mid-late PanINs but 
absent from wildtype controls (Commisso et al. 2013). Finally live in vivo studies have also 
shown in a similar GEMM of PDA (KrasLSL-G12D/+;TRP53loxp/loxp;Pdx1-cre) that pancreatic tumor 
cells, compared to adjacent non-cancerous cells, actively engage in macropinocytosis of labeled 
albumin, catabolizing proteins in order to utilize amino acids (Davidson et al. 2016). This 
evidence indicates that the transformed epithelial cells of PDA are responsible for nutrient 
scavenging through macropinocytosis in these tumors. It is also notable that in the live in vivo 
studies, treatment with either HCQ or EIPA inhibited the utilization of amino acids, 
demonstrating that these agents could be used as clinical therapeutics to inhibit 
macropinocytosis (Davidson et al. 2016).  
Lysosomal	  degradation	  	  
 
Both the autophagy and macropinocytosis culminate in the breakdown and release of 
cargo into the cytoplasm, a process carried out by lysosomes. Christian de Duve won the 1974 
Nobel Prize in Physiology or Medicine for his discovery of lysosomes in 1955 (Harnett et al. 
2017). He observed these entities breaking down both intra and extra cellular components. 
Since then lysosomal degradation has been characterized further and found to be dependent on 
both soluble hydrolases and integral lysosomal membrane proteins (Piao and Amaravadi 2016). 
The best-characterized hydrolases are the cytosolic cathepsins, which have opposing effects on 
tumor growth dependent on the location of their active site, cytosolic (growth inhibitory) or 
extracellular (growth promoting) (Repnik et al. 2012). LAMP-1 and LAMP-2 are the most 
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common integral membrane proteins, comprising 50% of these entities. These proteins 
participate in lysosome biogenesis, acidification, and selective autophagy. A second integral 
membrane protein critical to lysosomal functioning is vacuolar H+ -ATPase pump (V-ATPase), 
which drives the acidic pH by pumping hydrogen ions into the lysosomal lumen (Piao and 
Amaravadi 2016). These pumps have been targeted therapeutically with natural product 
inhibitors, which will be discussed in the scavenging inhibitors section.  
Scavenging	  pathway	  inhibition	  in	  cancer	  
 
  Inhibitors of the scavenging pathways can be categorized into upstream pathway 
inhibitors, lysosomal inhibitors and macropinocytosis inhibitors. Currently there are no specific 
inhibitors of autophagy; rather inhibitors of autophagy commonly target the lysosomal 
degradation pathway. Upstream pathway inhibitors include PI3K, EGFR, and mTORC1 
inhibitors. Both autophagy and macropinocytosis are regulated by RTKs, including EGFRs, 
making them sensitive to EGFR inhibition. However while EGFR inhibition reduces 
macropinocytosis, they have been shown to increase autophagy. Both of these pathways also 
depend on PI3K signaling mTORC1 activation. EGFR, PI3K, and mTORC1 are critical 
components of nutrient signaling pathways in general and thus are nonspecific in their effects. 
Downstream effectors of these pathways are numerous and effects of inhibition would be vast 
and nonspecific.  
Macropinocytosis inhibition has been accomplished through inhibitors of EGFR, PI3K, 
and mTORC1 (Grimmer, van Deurs, and Sandvig 2002; Palm et al. 2015). PI3K inhibition using 
LY294002 or wortmannin prevents macropinocytosis in cancer cells, among other cell types 
(Amyere et al. 2000). Consistent with this, phosphatidylinositol (PI) supplementation activates 
the GTPases, enzymes and other proteins required for actin polymerization at the membrane. 
Autophagy can also be inhibited using PI3K inhibitors that act against class III PI3K VPS34 or 
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mTORC1 inhibitors. Dual PI3K/mTOR inhibition was found to induce cancer cell death and 
block autophagy (Button et al. 2016). 
Chloroquine (CQ) and chloroquine derivatives are lysosomal inhibitors that are thought 
to prevent acidification by accumulating in lysosomes. As lysosomal acidification is a required 
step for their fusion with both autophagosomes and endosomes, these inhibitors also prevent 
autophagy and macropinocytosis. Unfortunately not much is known about the mechanism of CQ 
or how exactly it inhibits lysosomal functioning. CQ has been used clinically for almost a century 
as a preventative treatment against malaria. In contemporary studies involving the autophagy 
pathway, CQ is used as an inhibitor, however many of these studies neglect the fact that CQ is 
a lysosomal inhibitor. CQ prevents acidification of lysosomes and thus prevents their fusion with 
late endosomes and autophagosomes, which is dependent on the low lysosomal pH. When 
using CQ it is impossible to distinguish whether effects are due to autophagy or 
endocytosis/macropinocytosis inhibition. Is has been shown in studies that the growth inhibitory 
and chemo-sensitizing effect of CQ on cancer cells is autophagy autonomous, indicating that 
either the prevention of lysosomal acidification or off-target effects of CQ are responsible for 
these effects (Eng et al. 2016; Maycotte et al. 2012). 
Hydroxychloroquine (HCQ), a chloroquine derivative, is currently in clinical trials in PDA, 
among other cancers. While the agent is generally well-tolerated, high doses for prolonged 
periods of time are required to achieve the micromolar concentrations required for efficacy, 
shown in rheumatoid arthritis studies (Tett, Day, and Cutler 1993; Munster et al. 2002). For 
patients with PDA, who only live an average of 6 months after diagnosis, timing is critical and 
therapeutic concentrations within tumor tissue must be reached quickly. Therefore combination 
therapy with chemotherapeutics, coordinating pathway inhibition, or radiation is an attractive 
option. HCQ has been shown to sensitize cells and tumors to chemotherapy. Indeed HCQ is 
currently in PDA clinical trials in combination with standard of care treatment gemcitabine + 
Abraxane (Boone et al. 2015). Another option would be to inhibit scavenging pathways (with 
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CQ) in addition to nutrient sensing and generating pathways, including PI3K/AKT, mTORC1, 
MAPK/ERK and dnFAS. Scavenging pathways maintain cell survival by recycling nutrients such 
as proteins and lipids. If both the de novo generation and scavenging of these critical materials 
are inhibited, cells will essentially starve to death. A novel dimeric CQ, Lys05 has recently been 
described, that acts in a manner similar to CQ with more potent effects. This agent displayed 
significant toxicity, but could be explored in the future at lower doses (Amaravadi and Winkler 
2012).  
Another class of lysosomal inhibitors is V-ATPase inhibitors, which are natural products 
isolated from microbes, such as bafilomycin-A (Fais et al. 2007). V-ATPase inhibitors have been 
shown to attenuate cancer growth in vitro, in a xenograft model, and in the context of secondary 
drug resistance in breast cancer (von Schwarzenberg et al. 2014).  Pertinently, natural product 
isolated from marine sponges has displayed effects in PDA cells through V-ATPase and 
autophagy inhibition (Kallifatidis et al. 2013). Regrettably treatment with these agents has not 
been clinically relevant in cancer, as normal cells would be affected by V-ATPase inhibition as 
well.   
 The only macropinocytosis specific inhibitors are those blockers of Na+/H+ exchangers 
(NHEs), such as ethylisopropylamiloride (EIPA) (Koivusalo et al. 2010). The exact mechanism 
of macropinocytosis inhibition through EIPA is unknown, however it is known that the agent 
prevents Rac1 and Cdc42 signaling through the lowering of submembranous pH (Koivusalo et 
al. 2010). Importantly PDA cells express high levels of four different NHE isoforms, indicating 
that perhaps the increased levels of macropinocytosis seen in these cells has to do with 
expression of NHEs. EIPA has been shown to block macropinocytosis in vitro as well as in 
mouse models (Commisso et al. 2013).  
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Chapter	  4	  –	  Results	  
While it is known that pancreatic cancer cells undergo de novo fatty acid synthesis 
(dnFAS) at higher rates than normal cells and that overexpression of the key enzyme of this 
pathway, fatty acid synthase (FASN), is linked to tumor development, it is not known to what 
degree PDA is dependent on FASN activity for tumor maintenance (Li and Cheng 2014; Walter 
et al. 2009; Alo et al. 2007). We hypothesize that FASN overexpression is a survival mechanism 
through which pancreatic tumor cells endure the hypovascular and consequently nutrient-poor 
conditions of their microenvironment. We accomplished FASN inhibition in PDA both in vitro and 
in vivo using IPI-9119, a novel FASN inhibitor obtained from Infinity Pharmaceuticals. 
Importantly we show that treating FASN overexpressing cells with IPI-9119 induces apoptosis in 
the KPC mouse model of pancreatic cancer and in human pancreatic cancer cell lines, 
demonstrating that FASN is a potential therapeutic target for PDA. We also establish that, 
perhaps more so than dnFAS, PDA cells rely on the scavenging pathways, macropinocytosis 
and autophagy. In vitro work in human pancreatic cancer cell lines identified a dependence on 
lysosomal acidification and degradation of cargo, a step shared by both scavenging pathways. 
Utilizing a well-known lysosomotropic agent, chloroquine (CQ), which inhibits both autophagy 
and lysosomal degradation, we found that inhibiting both FASN and lysosomal function results 
in increased apoptosis in both human PDA cell lines and the KPfl/flC mouse model of pancreatic 
cancer. Additionally we observed decreased proliferation with dual inhibition of both scavenging 
pathways and dnFAS in KPfl/flC mouse tumors. These findings indicate that combination therapy 
with FASN and lysosomal inhibitors should be further explored as a pancreatic cancer 





FASN	  Expression	  in	  PDA	  
 
Aberrant FASN expression is found in many cancers, including pancreatic, where high 
expression levels are correlated with advanced tumor grade and poor patient prognosis. In a 
cohort of patients from Columbia University Medical Center (CUMC), higher FASN RNA 
expression levels occur in PDA versus PanIns, where expression is concentrated in oncogenic 
epithelial cells (Figure 2.1A-B). Pancreatic intraepithelial lesions (PanINs), pre-neoplastic 
lesions of the pancreas, have lower FASN RNA expression levels compared to overt carcinoma, 
reinforcing findings that high FASN expression is related to advanced disease. The mean FASN 
RNA expression levels in patient tumor samples with PDA versus those with PanINs were found 
to be statistically different, with PDA samples having higher FASN RNA expression (Mann 
Whitney U non-parametric statistical test with p<0.0001) (Figure 2.1A).  The mean FASN RNA 
expression level is also higher in the epithelial compartment compared with the stromal 
compartment, suggesting that aberrant FASN expression could be related to oncogenic 
metabolic reprograming that occurs in Kras mutated cells, which are constrained to the 
epithelium (Mann Whitney U non-parametric statistical test with p<0.0001) (Figure 2.1B). Past 
studies have shown that high FASN protein and RNA expression is related to poor prognosis in 
PDA and other cancers (Sánchez, Ph, and Draetta, n.d.). Indeed, employing data from a cohort 
of patients from University of North Carolina medical center, where patients are separated by 
highest and lowest quintile of FASN expression, we found that patients with high FASN 
expression have a poorer prognosis than those with low FASN expression (Kaplan-Meier Log-
rank statistical test with p<0.0229) (Figure 2.1C) (Moffitt et al. 2015). These data reiterate 
previous findings in pancreatic and other cancers where high FASN expression is an indicator of 
advanced tumor progression and reduced survival.  
To investigate the importance of FASN expression in pancreatic cancer we utilized the 
KPC mouse model, a clinically-predictive model of pancreatic cancer harboring K-ras and p53 
mutations. This model recapitulates the unique histopathology of human PDA in addition to 
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displaying similar clinical presentation, comorbidities, and chemotherapeutic resistance 
(Hingorani et al. 2005). Importantly, we found that KPC tumors mirror the FASN expression 
patterns of human PDA with strong FASN expression in the epithelium compared to the 
surrounding stroma (Figure 2.2C). Immunohistochemistry was performed to gauge FASN 
expression on a panel of 10 KPC mice. Positive expression can be seen in brown, which is 
concentrated in the epithelial cells. Lower expression is seen in the surrounding stroma, which 
is only stained by hematoxylin, a blue nuclear stain (Figure 2.2C). This relationship, high FASN 
expression in the epithelium and low FASN expression in the stroma, was evident in all 10 KPC 
mouse samples. A serial section was taken after each experimental slide to confirm the location 
of the epithelium and stroma by hematoxylin and eosin staining (Figure 2.2D). Normal-
appearing pancreatic tissue from a panel of 10 KPC mice whose tumors have not yet reached 
overt carcinoma display weaker FASN expression (Figure 2.2A-B), indicating that KPC PDA is 
similar to human PDA in that increased FASN expression is correlated with the development of 
PDA. A serial section was taken after each experimental slide to confirm that these samples are 
not PDA by hematoxylin and eosin staining (Figure 2.2B). The similarities between human PDA 
and KPC mouse PDA support the use of the KPC mouse as a preclinical model to study the role 
of FASN in PDA. 
Our hypothesis that FASN contributes to PDA growth and maintenance is based on the 
idea that FASN overexpression is a survival mechanism allowing PDA to thrive in a 
hypovascular and nutrient deficient microenvironment. Consistent with this, we found that FASN 
expression in KPC tumors is elevated in areas with lower vascularity whereas tumor cells 
directly adjacent to CD31 positive blood vessels have low FASN expression (Figure 2.2E-F). 
This descriptive analysis was performed on the same 10 KPC PDA mouse panel utilized for 
FASN staining. To determine whether high FASN expression occurs in low tumor vascularity 
areas we used dual color immunohistochemistry and probed for both FASN (brown) and a blood 
vessel marker, CD31 (purple). Additionally in these KPC tumor samples the PDA epithelium 
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displays an increased concentration of lipid droplets by Oil Red O staining when compared to 
the stroma, suggesting that FASN overexpression in these cells contributes to excessive lipid 
production from dnFAS (Figure 2.2G-H). Oil red O staining was performed on the same panel of 
10 KPC mice on adjacent frozen tumor samples. One potential explanation for these 
observations is that nutrient deprivation resulting from poor blood flow contributes to FASN 
over-expression and the lipogenic phenotype seen in PDA epithelium. Based on these results, 
we hypothesized that targeting FASN in a nutrient deficient microenvironment could result in 
attenuated growth and decreased survival in PDA cells.  
IPI-­‐9119	  inhibits	  FASN	  activity	  in	  vivo	  
	  
To target FASN in PDA tumors we utilized a small molecule FASN inhibitor, IPI-9119, 
provided by Infinity Pharmaceuticals. We began by confirming whether IPI-9119 was capable of 
inhibiting FASN in vivo in tumor tissue by conducting a pharmacology study in which 4 tumor-
bearing KPC mice were subjected to a biopsy surgery to obtain a pre-treatment sample. After 
surgery mice were treated for three days with IPI-9119 (q12h 200mg/kg) and sacrificed 4 hours 
the final treatment to obtain a post-treatment sample (Figure 3.1). Post-treatment samples were 
tested by mass spectrometry to determine whether IPI-9119 was present in tumor tissue. We 
found that IPI-9119 was efficiently delivered to KPC mouse tumors at concentrations found to 
be efficacious in xenograft model systems (Comparison xenograft figure is not shown: 
unpublished data from Infinity Pharmaceuticals)(Figure 3.2A). Furthermore, post-treatment 
tumor FASN activity was reduced by an average of 94% compared to matched pre-treatment 
samples, as measured by a FASN activity assay determining C13 labeled acetyl-CoA 
incorporation into palmitate (Figure 3.2B). These results confirm that IPI-9119 can potently 
inhibit FASN in tumor tissue and overcome the challenges of limited drug delivery commonly 
observed in pancreatic tumors. Utilizing IPI-9119 as a FASN inhibitor, we next explored the 
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short-term effects of FASN inhibition in KPC mouse tumors, with the goal of determining 
whether FASN activity is necessary for tumor growth and maintenance.  
IPI-­‐9119	  increases	  apoptosis	  in	  the	  epithelial	  compartment	  of	  KPC	  mouse	  PDA	  
	  
To determine whether FASN activity is necessary for PDA survival and maintenance in 
vivo, we next conducted an extensive study in KPC mice, using IPI-9119 to inhibit FASN. This 
intervention study, designed to uncover the short-term effects of FASN inhibition in vivo, 
consisted of two arms, vehicle and IPI-9119 with 6 mice per arm (Figure 3.3). Briefly, KPC mice 
were bred and screened for tumor development weekly by palpation. Following initial 
identification of tumor by palpation, tumor growth was quantified biweekly by 3D ultrasound until 
tumors reached 7-9 mm. At this point mice were randomized and enrolled into a study arm, 
either vehicle or IPI-9119. After enrollment in the IPI-9119 short-term intervention study, mice 
were treated for three days with IPI-9119 (q12h 200mg/kg) or vehicle, and sacrificed 4 hours 
after the final dose to retrieve tissue samples.  
In order to gauge short-term growth and survival in KPC mouse tumors, we performed 
immunohistochemistry on tumor samples probing for the proliferation marker phospho-histone 
H3 and the apoptosis marker cleaved caspase 3. Samples were taken from mice upon 
necropsy, fixed in formalin, paraffin embedded, and sectioned onto slides. 
Immunohistochemistry was performed as described in Methods. Counting was performed on 10 
random 40x fields per tumor. While we did not detect significant differences in the levels of 
proliferation and apoptosis in KPC mouse bulk tumors by counting positive cells (Mann-Whitney 
U statistical test: phospho-histone H3, p=0.231; cleaved caspase 3, p=0.999) (Figure 3.4G-H), 
upon visual examination it was evident that cleaved caspase 3 positive cells were largely 
restricted to the epithelial compartment, where high cleaved caspase 3 areas were evident 
adjacent to necrotic regions (Figure 3.4G-I). To assess apoptosis specifically in the epithelial 
compartment, we probed tumor tissue for both cleaved caspase 3 and the epithelial marker 
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cytokeratin 19 by two-color immunohistochemistry (Figure 3.5A-H). Dual staining of tumor tissue 
for cytokeratin 19 (brown) and cleaved caspase 3 (purple) demonstrated that IPI-9119 induced 
apoptosis was largely constrained to the epithelial compartment. Moreover, cleaved caspase 3 
positivity was significantly higher in the epithelial compartment of IPI-9119 treated KPC mouse 
tumors compared to vehicle control tumors (Mann-Whitney U statistical test, p=0.002) (Figure 
3.5I). There was no statistically significant difference between IPI-9119 and vehicle treated 
tumor CK19 positivity indicating that the number of epithelial cells in both groups is similar 
(Mann-Whitney U statistical test, p=0.180) (Figure 3.5J). These results suggest that FASN 
inhibition selectively induces apoptosis in malignant PDA epithelial cells as opposed to the 
surrounding stroma or in non-malignant cells. 
In light of our findings from CUMC patient PDA RNA expression data where we noted 
that FASN is more highly expressed in epithelial cells than stromal cells (Figure 2.1B), we 
hypothesized that the epithelial cells sensitive to IPI-9119 treatment would also be more 
dependent on FASN activity and therefore harbor high levels of FASN protein expression. To 
ascertain whether FASN inhibition specifically targets FASN overexpressing cells, we probed 
tumor tissues for both FASN and cleaved caspase 3 using two-color immunohistochemistry. We 
discovered that treatment with IPI-9119 induced apoptosis in FASN positive epithelial pockets 
and that areas of necrosis were often adjacent to regions with high numbers of double positive 
cells (Figure 3.6D-F). This effect was not observed in vehicle treated controls (3.6A-C). 
Quantification of double-positive cells per 40X field revealed a significant increase in apoptotic 
cells in FASN expressing cells (Mann-Whitney U statistical test, p=0.009, 10 counts per field 
with 6 mice per group) (Figure 3.6G). There was no statistically significant difference between 
IPI-9119 and vehicle treated tumor FASN positivity indicating that the number of FASN positive 
cells in both groups is similar (Mann-Whitney U statistical test, p=0.675, 10 counts per field with 
6 mice per group) (Figure 3.6H). These results indicate that FASN inhibition specifically targets 
FASN overexpressing cells. 
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While short-term FASN inhibition in the KPC mouse model did not have profound effects 
on the growth and survival of the entire tumor, it did induce targeted apoptosis in FASN 
overexpressing epithelial cells (Figure 3.5 & 3.6). Additional experiments will be required to 
explore the effects of long-term FASN inhibition therapy in the KPC model. A long-term survival 
study was attempted as part of this project; however due to issues of weight loss we were 
forced to abandon this avenue. In a tolerability study of IPI-9119 we found that dosing KC mice, 
mice with only a K-ras mutation, for longer than 2 weeks resulted in significant weight loss. 
Additional studies on drug tolerability included varied dosing regimens and alternative 
formulations, using an osmotic pump as opposed to oral administration of IPI-9119 
(Supplementary Figure 1). However all treatment regimens resulted in a 20% weight loss in a 
subset of mice. While it is possible that during long-term FASN inhibition, the cumulative stress 
of reduced lipid synthesis will lead to more pronounced levels of apoptosis, more studies are 
needed to determine an appropriate dosing regimen that does not result in weight loss. A long 
term study would also allow monitoring of tumor growth using 3D ultrasound to determine 
whether apoptosis caused by IPI-9119 treatment can slow total tumor growth. 
IPI-­‐9119	  modestly	  decreases	  viability	  in	  a	  subset	  of	  PDA	  cells	  in	  vitro	  
	  
 In order to further explore the relationship of dnFAS with other aspects of lipid 
metabolism, we moved to an in vitro human PDA cell culture system. It was previously reported 
that ~95% of fatty acids in human pancreatic cancer cells are synthesized de novo, indicating 
that these cells are particularly dependent on dnFAS and thus FASN activity (Li and Cheng 
2014). To establish if FASN activity is critical for human PDA cell survival we treated 4 human 
PDA cell lines (Miapaca2, PANC1, ASPC1, and BXPC3) with various doses of IPI-9119 and 
assessed cell viability (Figure 4). In these and all future in vitro experiments cells were treated in 
1% charcoal stripped media to recapitulate the nutrient replete conditions of the PDA 
microenvironment. Viability percentages for each dosage of IPI-9119 were obtained using the 
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Alamar Blue cell viability assay, where all values were normalized to a DMSO control. Each 
value is the mean values +/- SEM from 3 biological replicates each consisting of 4 technical 
replicates. Surprisingly we found that the restriction of the dnFAS pathway using IPI-9119 
effects human pancreatic cell viability modestly with only a 20-30% reduction in viability in two 
cell lines, Miapaca2 and PANC1, over a five day period in nutrient restricted conditions (Figure 
4A,B). In these two cell lines, a dose response relationship was evident with IPI-9119 treatment 
(GraphPad Prism four parameter variable slope model of log(inhibitor) vs. response curves) 
(Figure 4A,B). However, the total magnitude of inhibition of cell viability at the highest doses of 
IPI-9119 was modest. By comparison, two cell lines, ASPC1 and BXPC3, were insensitive to 
treatment with IPI-9119 (Figure 4C,D). These results indicate that, at least in the context of 2-
dimensional culture conditions, PDA cells are not as dependent on dnFAS as we had expected 
based on our in vivo data. One possible explanation for human cell lines’ insensitivity to FASN 
inhibition may be the activation of scavenging pathways such as autophagy or 
macropinocytosis, which have both been shown to be factors in PDA. These scavenging 
pathways may allow cells to survive during FASN inhibition.  
Scavenging	  pathways	  support	  PDA	  cell	  survival	  in	  the	  absence	  of	  FASN	  activity	  
	  
The finding that FASN inhibition only modestly decreases PDA cell viability in vitro, and 
in only a subset of cell lines, prompted us to investigate alternative methods of lipid 
maintenance. While is has been shown in vitro that PDA cells utilize dnFAS lipids, lipids may 
also be obtained from scavenging pathways (Li and Cheng 2014; J. J. Kamphorst et al. 2013). 
We hypothesized that PDA cells may be able to overcome lipid scarcity caused by FASN 
inhibition via the scavenging pathways, autophagy and macropinocytosis. Indeed, both 
increased flux through the autophagy pathway and elevated levels of macropinocytosis have 
been reported in PDA cell lines and in vivo. Elevated levels of macropinocytosis have been 
shown in human PDA cell lines, where cells actively scavenge protein nutrients, and in ex vivo 
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tumors slices from patients, where labeled dextran is internalized by cells (Commisso et al. 
2013; Jurre J. Kamphorst et al. 2015). Furthermore, macropinosomes were detected KPloxp/loxpC 
mouse PanINs indicating that macropinocytosis is activated during tumorigenesis (Commisso et 
al. 2013). PDA growth has also been shown to be dependent on autophagy in the KPC mouse 
model, where treatment with hydroxychloroquine (HCQ) reduced tumor growth and increased 
survival (S. Yang et al. 2011). HCQ, after performing well in Phase I pharmacology studies, is 
currently in Phase II human clinical trials in combination with gemcitabine/Abraxane 
(www.clinicaltrials.gov; Boone et al. 2015).  This evidence suggests that scavenging pathways 
are activated in PDA and contribute to nutrient maintenance. Accordingly, we next aimed to 
establish whether autophagy and macropinocytosis are mechanisms of primary resistance to 
FASN inhibition allowing PDA cells bypass their dependence on dnFAS. 
To determine whether scavenging pathways provide lipids to PDA cells during FASN 
inhibition, we blocked these pathways pharmacologically in the context of FASN inhibition, and 
assessed cell viability. To inhibit scavenging pathways in human cell lines we treated cells with 
chloroquine (CQ), which inhibits both autophagy and macropinocytosis by preventing the 
acidification of lysosomes, thereby preventing the degradation of all cargo. Miapaca2, PANC1, 
ASPC1, and BXPC3 cell lines were treated with 7.5 µM CQ and various doses of IPI-9119 in 
media with 1% charcoal-stripped serum.  We found that the two cell lines most sensitive to 
monotherapy IPI-9119, Miapaca2 and PANC1, maintained a dose response relationship with 
FASN inhibitor IPI-9119 in the context of CQ treatment, indicating that these cell lines remain 
sensitive to FASN inhibition when scavenging is inhibited (GraphPad Prism four parameter 
variable slope model of log(inhibitor) vs. response curves). CQ alone reduced viability by about 
50-60% in the Miapaca2 and PANC1 cell lines and dual inhibition reduced viability by 75-85%, 
demonstrating that while these cell lines are affected by both FASN and CQ, they are more 
sensitive to CQ (Figure 5.1A,B). While the two IPI-9119 insensitive cell lines, ASPC1 and 
BXPC3, did not show a dose response relationship to IPI9119, they were affected by treatment 
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with CQ with reductions in viability between 75-95% (GraphPad Prism four parameter variable 
slope model of log(inhibitor) vs. response curves) (Figure 5.1C,D). Dose response curves with 
the addition of CQ were performed in a similar manner to those without CQ (Figure 4). In 
summary, all four human cell lines, regardless of their sensitivity to FASN inhibition, were 
sensitive to CQ, which induced a significant decrease in viability in all cell lines (Two-way 
ANOVA statistical test between serum conditions where *p<0.0001) (Figures 5.1A-D). From 
these results, we can infer that scavenging pathways may contribute to FASN inhibition 
resistance in human PDA cell lines.  
We next investigated the cause of decreases in human cell viability with dual CQ and 
IPI-9119 treatment. Significant decreases in cell viability could indicate apoptosis, necrosis, or 
cell cycle arrest. We hypothesized that these cells are undergoing apoptosis based on our 
findings in vivo where  KPC mouse PDA epithelial cells treated with IPI-9119 displayed greater 
levels of apoptosis than controls. To assess levels of apoptosis we treated human PDA cell 
lines, Miapaca2, PANC1, ASPC1, and BXPC3 with DMSO control, CQ (7.5 µM), IPI-9119 (20 
nM), and IPI-9119+CQ and probed collected lysates for apoptosis marker cleaved caspase 3 by 
immunoblot. We found that dual therapy with IPI-9119 and CQ induced significant apoptosis in 3 
human PDA cell lines when compared to controls (Kruskal-Wallis non-parametric multiple 
comparisons mean rank test compared to control) (9119+CQ treatment: Miapaca2, p=0.014; 
PANC1, p=0.014; and BXPC3, p=0.038) regardless of FASN inhibition sensitivity indicating that 
all cell lines are sensitive to combination FASN inhibition and scavenging inhibition (Figure 5.2). 
Unsurprisingly, when cell lines are compared against each other the more IPI-9119 sensitive 
cell lines in the cell viability assay (Figure 4) also display the greatest apoptotic effect with both 
IPI-9119 monotherapy and dual therapy with IPI-9119 and CQ (Figure 5.2F). From these 
findings it seems that the inhibition of both FASN activity and the scavenging pathways has the 
greatest effect on PDA growth and maintenance.  
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After finding that IPI-9119 + CQ treatment induces significant apoptosis in 3 human PDA 
cell lines, we next wanted to determine whether dual treatment alters the cell cycle profile of 
PDA cell lines. Cell cycle arrest is another potential explanation for the reductions in cell viability 
seen in dose response curves (Figure 5.1).  FASN inhibition has been reported to cause G1/S 
arrest, thus we hypothesized that reductions in cell viability in the more IPI-9119 sensitive cell 
lines, Miapaca2 and PANC1, could be partially due to changes in cell cycle. We performed cell 
cycle analysis on DMSO control, CQ (7.5 µM), IPI-9119 (20 nM) and IPI-9119 + CQ and treated 
cells. To assess cell cycle state we used 7-Aminoactinomycin D (7-AAD) to quantify DNA 
content in permeabilized, ethanol-fixed cells (Figure 5.3). We only saw significant changes in 
cell cycle with IPI-9119 monotherapy in one cell line, PANC1, where IPI-9119 treatment 
modestly increased the percentage of cells in G1 (Kruskal-Wallis non-parametric multiple 
comparisons test compared to control, * p<0.05) (Figure 5.3E). This is a documented effect of 
FASN inhibition that has been shown in various cancer cell lines using FASN inhibitors, C75 
and Orlistat (Knowles et al. 2004; Gao et al. 2006) We found that dual treatment produced a 
modest G1 arrest in the more FASN sensitive cell lines, Miapaca2 and PANC1, but not in cell 
lines that were less sensitive to FASN inhibition, ASPC1 and BXPC3 (Kruskal-Wallis non-
parametric multiple comparisons test compared to control, * p<0.05) (Figure 5.3D-G). It is 
interesting that only FASN sensitive cell lines exhibited significant G1 arrest, an indication that 
G1 arrest might contribute to the mechanism of FASN inhibition sensitivity.  
Dual	  IPI-­‐9119	  and	  chloroquine	  treatment	  effects	  are	  mediated	  by	  macropinocytosis	  rather	  
than	  autophagy	  
	  
As CQ inhibits both autophagy and macropinocytosis we next sought to determine 
whether autophagy specifically is able to provide lipids in the context of FASN inhibition. We 
hypothesized that if PDA cells rely on autophagy to provide lipids during FASN inhibition, this 
pathway will be upregulated in PDA cells when treated with IPI-9119. To specifically determine if 
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PDA cell lines have an increased dependency on autophagy in the context of FASN inhibition 
we measured autophagosome flux in control and IPI-9119 treated cells. If PDA cells are 
obtaining lipids from autophagy during FASN inhibition, flux through the pathway should 
increase with IPI-9119 treatment, compensating for a shortage of lipids from dnFAS. To assess 
autophagosome flux we treated human PDA cell lines with DMSO, CQ, IPI-9119 and IPI-
9119+CQ for 48 hours, and measured changes in levels of LC3B-II protein by Western blot. The 
change in levels of LC3B-II protein between the DMSO control sample and the chloroquine 
treated sample is the basal autophagic flux of a given cell line. This basal flux was compared to 
the autophagic flux of samples treated with IPI-9119 for 48 hours. We detected no significant 
differences between basal autophagic flux and IPI-9119 treatment autophagic flux in the four 
human PDA cell lines, Miapaca2, PANC1, ASPC1 and BXPC3 (Mann-Whitney U non-
parametric statistical test: Miapaca2, p=0.900; PANC1, p=0.900; ASPC1, p=0.400; BXPC3, 
p=0.700) (Figure 6). Given the drastic reduction in cell viability with CQ treatment, we expected 
that autophagy would be upregulated during FASN inhibition, serving as a mechanism of 
resistance during lipid insufficiency. It is possible that although autophagic flux is not increased 
with IPI-9119 treatment basal flux through the autophagy pathway is enough to provide primary 
resistance to PDA cells. Another explanation for these results is that PDA cells are dependent 
more broadly on lysosomal function and degradation, which is also prevented by CQ, rather 
than autophagy. 
To directly assess the dependency of PDA cells on autophagy during FASN inhibition, 
we next ablated autophagy genetically in the context of FASN inhibition. To accomplish this, we 
utilized three doxycycline inducible ATG4 dominant negative KPC mouse cell lines, 5896, 6287, 
6406, and treated cells with doxycycline (DOX) at 1 µg/mL and various increasing dosages of 
IPI-9119 (ATG4 dominant negative cell lines were kindly provided by Dr. Alec Kimmelman from 
NYU). ATG4 is a critical autophagy protein that acts as a part of a complex with several other 
ATG proteins and is responsible for the growth and elongation of the autophagosome 
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membrane. As a part of this complex, ATG4 generates the membrane-associated form of LC3B, 
LC3B-II, from cytosolic LC3B-I (Feng et al. 2014). LC3B-II is present on the membrane of all 
autophagosomes, functions to expand vesicles and select cargo, and is used as a common 
marker to assess levels of autophagy experimentally (Harnett et al. 2017). Without the 
functioning ATG4 protein, LC3B-I cannot be lipidated to form LC3B-II, halting the formation of 
autophagosomes and causing LC3B-I accumulation in the cell. To test the validity of the 
doxycycline inducible cell lines we treated ATG4 dominant negative cells with doxycycline for 
three days. Levels of LC3B-I, assessed by immunoblot, were increased in doxycycline cells 
when compared to controls (n=3), indicating that the autophagy pathway is inhibited (Figure 
7A).  
To determine whether PDA cells have primary resistance to FASN inhibition through the 
autophagy pathway we treated both doxycycline induced cells (+DOX) and control cells (-DOX) 
with IPI-9119 for five days. We would expect that the autophagy deficient cells would be more 
sensitive to IPI-9119 than control cells if autophagy were a mechanism of primary resistance for 
FASN inhibition. Unexpectedly, there was no significant difference between autophagy-deficient 
cell lines and their normal counterparts after treatment with IPI-9119, demonstrating that 
autophagy is not responsible for promoting the survival of these cell lines in the absence of 
dnFAS (Two-way ANOVA statistical test between serum conditions where p>0.999) (Figure 
7B,C). We had anticipated that using genetic and pharmacological means to inhibit autophagy 
would yield comparable results, producing similar IPI-9119 dose response curves.  
These results indicate that PDA cell sensitivity to CQ following FANS inhibition is due to 
the contribution of lysosomal acidification to processes other than autophagy. To confirm this, 
treated the ATG4 dominant negative mouse cell lines with both doxycycline (1 µg/mL), to induce 
autophagy ablation, and CQ (7.5 µM) (Figure 7). If CQ were simply causing autophagy inhibition 
the effect of CQ treatment on these cells would be negligible as pharmacological autophagy 
inhibition is redundant in cells that are already genetically autophagy deficient. However, when 
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we treated autophagy deficient cell lines with CQ we observed a significantly different IPI-9119 
dose response curve (Two-way ANOVA statistical test between serum conditions where 
*p<0.0001). Futhermore +DOX+CQ curves were similar to curves treated with CQ alone 
indicating that CQ’s effects are more extensive than autophagy inhibition (Two-way ANOVA 
statistical test between serum conditions where p>0.999) (Figure 7B-D). PDA cell lines’ high 
sensitivity to CQ implies that perhaps more than autophagy, PDA cells are dependent on 
lysosomal function and the ensuing breakdown of cargo. As both autophagy and 
macropinocytosis are elevated in PDA and both utilize the lysosomal pathway as their terminal 
step, these findings led us to ask whether macropinocytosis could allow PDA cells to survive 
and proliferate in the absence of FASN activity. 
Macropinocytosis	  contributes	  to	  the	  resistance	  of	  PDA	  cells	  to	  FASN	  inhibition	  in	  vitro	  
	  
 Our finding that the effects of chloroquine on FASN inhibited PDA cells are independent 
of autophagy led us to investigate the contribution of macropinocytosis to lipid maintenance. 
Macropinocytosis is a scavenging pathway through which cells can internalize external nutrients 
by extending the plasma membrane into the extracellular space. The resulting internalized 
double membrane structures, macropinosomes, eventually fuse with lysosomes and cargo is 
degraded providing cells with a range of exogenous nutrients including proteins, amino acids, 
and lipids (Sousa and Kimmelman 2014). Both PDA cell lines and in ex vivo tumor slices have 
high levels of macropinocytosis and it has been shown that PDA cells actively scavenge amino 
acids from the extracellular environment through this pathway (Jurre J. Kamphorst et al. 2015; 
Commisso et al. 2013). As the macropinocytosis pathway also requires lysosomal degradation, 
we next decided to explore macropinocytosis as a potential source of lipids in PDA and a 
mechanism of primary resistance to FASN inhibition.  
To determine if macropinocytosis is a mechanism of primary resistance during FASN 
inhibition we utilized macropinocytosis inhibitor ethylisopropylamiloride (EIPA), a Na+/H+ 
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exchange blocker, and treated human PDA cell lines: Miapaca2, PANC1, ASPC1, and BXPC3, 
with EIPA (10 µM) and various doses of IPI-9119 (Figure 8.1). EIPA has been shown to 
specifically inhibit macropinocytosis without affecting other endocytosis pathways (West, 
Bretscher, and Watts 1989; Dowrick et al. 1993). We found that Miapaca2, ASPC1, and BXPC3 
cell lines were significantly more sensitive to FASN inhibition in the context of macropinocytosis 
inhibition with decreases in viability at 90%, 45% and 80% respectively (Two-way ANOVA 
statistical test between serum conditions where *p<0.0001) (Figure 8.1 A, C, D). These cell lines 
also displayed a dose response relationship with IPI-9119 in the context of EIPA treatment 
(GraphPad Prism four parameter variable slope model of log(inhibitor) vs. response curves). 
These results indicate that lipid maintenance during FASN inhibition maybe supported by 
macropinocytosis in these three cell lines. The reliance of ASPC1 and BXPC3 cells on 
macropinocytosis also offers a potential explanation as to why these cell lines are insensitive to 
FASN inhibition monotherapy. We next wanted to determine the mechanism causing decreased 
viability in the three macropinocytosis sensitive cell lines. We hypothesized that these cells are 
undergoing apoptosis under the influence of dual FASN and macropinocytosis inhibition, as we 
found was the case with FASN and CQ dual therapy.  
To reveal whether macropinocytosis inhibition sensitive cell lines are undergoing 
apoptosis when subjected to dual FASN and macropinocytosis inhibition, we treated cell lines 
with DMSO control, EIPA (10 µM), IPI-9119 (20 nM), IPI-9119 + EIPA for 48 hours and probed 
cell lysates for apoptosis marker cleaved caspase 3 by immunoblot (Figure 8.2). We expected 
that all macropinocytosis sensitive cell lines, ASPC1, BXPC3, and Miapaca2 would undergo 
increased apoptosis with EIPA treatment. Additionally, we predicted that the cell lines less 
sensitive to FASN inhibition, ASPC1 and BXPC3, would undergo apoptosis when treated with 
EIPA + IPI9119, based on previous cell viability results (Figure 8.1). While none of the cell lines 
exhibited significantly increased levels of cleaved caspase 3 with EIPA treatment, we found that 
FASN inhibition insensitive cell lines, ASPC1 and BXPC3, displayed increased levels of cleaved 
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caspase 3 when treated with IPI-9119 + EIPA (Figure 8.2D,E). Surprisingly, although Miapaca2 
cells are sensitive to IPI-9119 in the context of macropinocytosis inhibition, dual inhibition did 
not significantly increase levels of cleaved caspase 3 (Kruskal-Wallis non-parametric multiple 
comparisons mean rank test compared to control, 9119+EIPA treatment: Miapaca2, p=0.125) 
(Figure 8.2B). PANC1 cells, which displayed no decrease in viability with dual treatment 
compared to FASN inhibition alone, did not have significantly increased levels of cleaved 
caspase 3 with dual inhibition, as expected (Kruskal-Wallis non-parametric multiple 
comparisons mean rank test compared to control, 9119+EIPA treatment: PANC1, p=0.071) 
(Figure 8.2C). Both Miapaca2 and PANC1 cell lines displayed statistically significant increases 
in apoptosis with both IPI-9119 monotherapy (Kruskal-Wallis non-parametric multiple 
comparisons mean rank test compared to control, 9119+EIPA treatment: Miapaca2, p= 0.028; 
PANC1, p=0.049) (Figure 8.2B,C). These findings may offer a clue to the reason behind ASPC1 
and BXPC3 insensitivity to FASN inhibition. While these two cell lines are not sensitive to FASN 
inhibition alone, they display decreased viability and increased apoptosis when subjected to 
dual inhibition using IPI-9119 and EIPA (Kruskal-Wallis non-parametric multiple comparisons 
mean rank test compared to control, 9119+EIPA treatment: ASPC1, p= 0.038; BXPC3, 
p=0.020) (Figure 8.2D,E). This sensitivity to FASN inhibition in the context of macropinocytosis 
inhibition indicates that macropinocytosis may be a mechanism of primary resistance to FASN 
inhibition in the more FASN insensitive cell lines, ASPC1 and BXPC3.  
Dual	  inhibition	  of	  FASN	  and	  lysosomal	  function	  in	  vivo	  
	  
From our in vitro work exploring the scavenging pathways, autophagy and 
macropinocytosis, as mechanisms of primary resistance to FASN inhibition, we concluded that 
macropinocytosis may account for primary resistance to FASN inhibition in the more FASN 
inhibition insensitive cell lines, ASPC1 and BXPC3. However, a treatment that inhibits both 
pathways would be ideal, as we know both pathways are active in PDA cells and we were not 
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able to experimentally determine how meaningfully autophagy contributes to lipid maintenance. 
When using CQ as an inhibitor of autophagy we found that the agent had effects beyond 
autophagy inhibition, presumably due to its lysosomotropic effects. Treatment with CQ and IPI-
9119 decreased cell viability in all cell lines drastically, regardless of sensitivity to FASN inhibitor 
IPI-9119 or macropinocytosis inhibitor EIPA. Indeed, although clinical pharmacodynamic trials 
using CQ have reported variable efficacy of the drug at reducing autophagosome flux, there is 
evidence that CQ’s effects, chiefly sensitizing cancer cells to chemotherapy, are independent of 
autophagy (Boone et al. 2015; Maycotte et al. 2012). As dual treatment with IPI-9119 and CQ 
was the most effective therapeutic and there is some evidence that CQ inhibits both scavenging 
pathways, we decided to explore dual inhibition with IPI-9119 and CQ in vivo in the KPC mouse 
model.   
Our finding that dual treatment with IPI-9119 and CQ decreases cell viability in PDA cell 
lines through the induction of apoptosis prompted investigation in an in vivo model. We already 
witnessed a significant induction of apoptosis in KPC mouse epithelial tumor cells with IPI-9119 
monotherapy. We hypothesized that dual therapy with IPI-9119 and CQ would result in a more 
pronounced apoptosis effect based on our in vitro data. To conduct a short-term intervention 
study with IPI-9119 and CQ we utilized the KPfl/flC mouse model, a model similar to the KPC 
model with the exception of p53 status. The KPfl/flC model harbors a conditional knockout of 
both p53 alleles as opposed to the R172H heterozygous p53 mutation in the KPC model. This 
model has the advantage of an expedited tumor development of 4-6 weeks compared to the 
KPC model, in which mice develop tumors around 2 months.  
To inhibit both FASN and scavenging pathways in vivo we administered hydroxychloroquine 
(HCQ), a derivative of chloroquine that well tolerated in humans and utilized in clinical trials, and 
IPI-9119 to KPfl/flC mice. HCQ requires two weeks to achieve pharmacodynamic effectiveness 
clinically (Boone et al. 2015). Accordingly, we treated mice with HCQ at 60 mg/kg daily as soon 
tumors were detected by palpation (at about 6 weeks) and continued treatment for two weeks, 
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after which IPI-9119 was administered at 200 mg/kg for three days every 12 hours (Figure 9.1). 
Dual therapy induced significant apoptosis in the KPfl/flC mouse tumors by immunohistochemical 
staining of marker cleaved caspase 3 when compared to controls (Kruskal-Wallis non-
parametric multiple comparisons mean rank test compared to control, 9119+CQ, p=0.007). This 
effect was seen in bulk tumor sections, indicating that dual therapy is more effective at inducing 
apoptosis than IPI-9119 monotherapy (Figure 9.2J). Additionally, combination treated tumors 
displayed significantly lower levels of proliferation by immunohistochemical staining of marker 
phospho-histone H3 (Kruskal-Wallis non-parametric multiple comparisons mean rank test 
compared to control, 9119+CQ, p=0.026) (Figure 9.2I). Increased apoptosis and reduced 
proliferation levels were not restricted to the epithelial compartment, as with IPI9119 
monotherapy, rather effects were seen throughout the tumor.  
We next sought to determine if, as with IPI-9119 monotherapy, dual therapy induces 
more profound apoptosis effect in the epithelial compartment of tumors. To accomplish this we 
performed dual immunohistochemistry probing for cleaved caspase 3 and epithelial marker, 
cytokeratin-19 (Figure 9.3). We found that while there is an upward trend of double positivity in 
the dual IPI-9119 and HCQ treated mouse tumors, there was no significant difference compared 
to controls (Kruskal-Wallis non-parametric multiple comparisons mean rank test compared to 
control, 9119+CQ, p=0.121) (Figure L). However, we did observe focal areas of strong 
apoptosis in the epithelium in dual treated tumors, an effect that was not reflected by counting 





































































Chapter	  5	  –	  Discussion	  
While pancreatic cancer cells have been shown to display increased flux through the 
dnFAS pathway and the expression of key enzyme FASN is correlated to poor prognosis in 
PDA patients, the targeting of the dnFAS pathway through FASN inhibition has never been 
attempted in an in vivo model of PDA (Li and Cheng 2014; Walter et al. 2009; Alo et al. 2007). 
Here we demonstrated that FASN inhibition, using a small molecule inhibitor IPI-9119, induced 
apoptosis specifically in the epithelial cells of PDA tumors particularly those expressing FASN, 
in the KPC mouse model of pancreatic cancer. This finding supports the conclusion that 
malignant epithelial cells depend at least partially on dnFAS activity via FASN. However when 
investigating the mechanism of this effect in vitro, we found that PDA cell lines were largely 
insensitive to FASN inhibitor treatment. We hypothesized that this insensitivity might be due to 
aberrant activity through scavenging pathways, which are known to be activated following 
mutant K-ras metabolic reprogramming (A. Yang et al. 2014; J. J. Kamphorst et al. 2013; 
Commisso et al. 2013).  In vitro studies in human PDA cell lines revealed that scavenging 
pathways, particularly macropinocytosis, can contribute to FASN inhibitor resistance. 
Combination inhibition with IPI-9119 and the lysosomal inhibitor chloroquine (CQ), substantially 
reduced viability in PDA cell lines through apoptosis, suggesting that lysosomal degradation is 
critical for PDA growth and maintenance, particularly in the context of FASN inhibition. The 
macropinocytosis specific inhibitor EIPA in combination with IPI-9119 reduced viability via 
increased apoptosis in cell lines more insensitive to IPI-9119 monotherapy, suggesting that in 
these cell lines scavenged lipids may confer primary resistance during FASN inhibition. Indeed it 
has been shown that PDA cells actively scavenge albumin, amino acids, and lipids from the 
extracellular environment (Commisso et al., 2013; Jurre J. Kamphorst et al., 2015). In vivo 
studies using IPI-9119 and hydroxychloroquine (HCQ) dual therapy induced apoptosis and 
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reduced proliferation in tumors of the KPfl/flC model of pancreatic cancer, suggesting that 
blocking dnFAS and lysosomal degradation could be an effective therapeutic strategy in PDA.  
While FASN inhibition has been previously utilized as a therapeutic strategy in mouse 
models of melanoma and breast cancer, this is the first time that FASN inhibition has been used 
in a preclinical pancreatic cancer mouse model. FASN inhibition in a mouse model of melanoma 
decreased both metastases and angiogenesis and a study utilizing the Neu-N mouse model of 
breast cancer has shown that FASN inhibition is chemopreventive (Seguin et al. 2012; Alli et al. 
2005). Our findings in the KPC model suggest that PDA’s particular structural and 
pathophysiological elements may benefit from FASN inhibition. PDA is composed of multiple 
cell types that populate two distinct compartments. The epithelium, consisting of oncogenic K-
ras transformed cells, is homogenous and responsible for the initial transformative insult of 
PDA. Although early stage efforts to target these cells are currently in clinical evaluation, for 
example antisense oligonucleotide AZD4785 is in Phase I clinical trials for solid tumors; most 
work to date has been largely unsuccessful (www.clinicaltrials.gov). Therefore targeting 
programs downstream of K-ras metabolic reprogramming is an attractive alternative strategy to 
bypass this difficulty. While numerous efforts have been made recently to target various 
components of the pancreatic tumor stroma, results have been mixed to date and at least some 
elements of the stroma can restrain cancer rather than promote it (Rhim et al. 2014). Thus 
targeting the epithelium is an important, if challenging, priority for this disease. We found that 
IPI-9119 monotherapy was effective in targeting these cells, in particular those overexpressing 
FASN, causing apoptosis (Figures 3.5, 3.6). More research is needed to determine if FASN 
inhibition is a viable therapeutic strategy long-term and whether this apoptosis effect can reduce 
tumor growth. 
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IPI-­‐9119	  tolerability	  and	  long-­‐term	  treatment 
Oral gavage dosing of IPI-9119 (200 mg/kg twice a day) in KPC mice over a period of 
two weeks resulted in weight loss when administered with the standard of care 
chemotherapeutic for PDA, gemcitabine (Data not shown). As a part of our attempt to find a 
more tolerable regimen we investigated the pharmacology of an IPI-9119 formulation 
administered in a subcutaneous implanted two-week osmotic pump. Due to solubility restraints 
of the drug and the limited size of the pump we could only dose mice with half of the amount 
given with the oral gavage formulation, equivalent to 200 mg/kg daily as opposed to two doses 
of 200 mg/kg daily at 12-hour timepoints. Accordingly we observed a lower level of FASN 
inhibition in these mouse tumors ~80% vs. >95% with the oral formulation. In order to boost the 
efficiency of the inhibitor we explored treatment with both the osmotic pump and oral gavage. 
While treatment with the osmotic pump alone was tolerable, none of the combination treatments 
were tolerable in KC mice and a survival study was eventually abandoned (Supplementary 
Figure 1). These studies were completed while we were characterizing IPI-9119 in the KPC 
mouse as a monotherapy. It would be interesting to see if combination therapy with the IPI-9119 
osmotic pump and HCQ is tolerable long-term. The acute apoptosis caused by short-term 
treatment indicates that combination treatment with a FASN inhibitor and a lysosomal inhibitor is 
more effective. It may be possible to treat mice with lower concentrations of IPI-9119 when in 
combination with HCQ making the regimen more tolerable while still achieving the desired 
effect.  
In	  vivo	  versus	  in	  vitro	  effects	  of	  IPI-­‐9119	  
 
In vivo, in the KPC mouse model of pancreatic cancer, we found that FASN 
overexpressing epithelial cells were particularly sensitive to IPI-9119 monotherapy in short-term 
studies. IPI-9119 induced apoptosis in ~20% of counted epithelial cells vs. ~5% in vehicle 
controls and in ~30% of counted FASN positive cells vs. ~15% of vehicle controls (Figure 3.5, 
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3.6). Accordingly we expected a greater response in PDA epithelial cell lines in vitro, as cell 
culture contains only epithelial cells. Surprisingly these cells were less sensitive, with two lines 
displaying small decreases in cell viability and two cell lines displaying no response to treatment 
(Figure 4). There could be several reasons for this divergence in effect. One likely explanation is 
the different microenvironment present in cell culture versus an in vivo tumor. Cell culture 
environment is 2-dimensional, lacks a stroma, and only contains epithelial cells while the tumor 
microenvironment contains both epithelium and stroma in a 3-dimensional structure. The 
presence of a dense fibrous stroma surrounding oncogenic epithelial cells is a defining feature 
of pancreatic cancer. Unfortunately 2-dimensional cell culture environments cannot capture 
these conditions.. In vivo the stroma can physically block access to nutrients, including oxygen 
and lipids, by limiting the epithelial cells’ extracellular space and restricting blood vasculature.  
As mentioned previously, pancreatic cancers have been found to uptake nutrients from 
their extracellular environment through macropinocytosis. While inhibiting FASN alone in vitro 
had modest effects on cell viability in only two cell lines, Miapaca2 and PANC1 (Figure 4), we 
found that inhibiting both FASN and macropinocytosis, using IPI-9119 and EIPA, was more 
effective in three of the four cell lines tested Miapaca2, ASPC1 and BXPC3 (Figure 8.1). 
Previous experiments performed in the Olive lab have showed that Miapaca2 cells have high 
basal levels of macropinocytosis while PANC1 cells have very low basal levels of 
macropinocytosis (Supplementary Figure 2). Unsurprisingly the PANC1 cell line did not have a 
response to macropinocytosis inhibitor EIPA, and retained the same dose response relationship 
with IPI-9119 even with added EIPA. Miapaca2 cells retained sensitivity to IPI-9119 with 
additional EIPA treatment leading to greater viability reductions as would be expected due to 
these cells’ dependence on macropinocytosis. Both ASPC1 and BXPC3 cell lines showed no 
reductions in viability when treated with IPI-9119 alone (Figure 4). However the addition of EIPA 
in the context of FASN inhibition caused drastic reductions in viability (Figure 8.1). In 2-
dimensional culture epithelial cells have more access to the extracellular environment and are 
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not impinged by an encapsulating stroma. FASN inhibition may place a selective or adaptive 
pressure on epithelial cells to become more reliant on macropinocytosis while extracellular lipids 
are available. In vitro cells may have more access to nutrients provided by macropinocytosis 
due to 2-dimensional cell culture conditions, allowing for them to escape the pressures of FASN 
inhibition. On the other hand macropinocytosis may not be as great of a survival benefit in vivo 
as the stroma limits access to nutrients. Experimentally we treated cells in media containing 
only 1% charcoal stripped FBS to mimic PDA’s nutrient poor environment. However it is 
possible that even this amount of extracellular lipids is enough for PDA survival during dnFAS 
inhibition. An experiment involving 3-dimensional organoid co-cultures or tumor slice cultures 
from KPC mice would help to further explore the differences between FASN inhibition in 
epithelial cells with and without the tumor microenvironment. These methods involve the co-
culturing of epithelium and stroma leading to a microenvironment that resembles in vivo tumors 
more accurately. If these culture systems, with more intact tumor microenvironments, have a 
greater sensitivity to FASN inhibition then it is more likely that the reason for in vitro cell line 
insensitivity to FASN treatment is their specific 2-dimensional microenvironment.  
Another difference between in vivo experiments and cell culture experiments is oxygen 
supply. The dense stroma of PDA leads to poor tissue perfusion. Indeed, unpublished 
experiments from our laboratory have demonstrated that the partial pressure of oxygen in vivo 
in tumors from the KPC mouse model is under 1mmHg, demonstrating extreme hypoxia. 
Hypoxia chambers do not generally reach this low an oxygen concentration, making 
experiments mimicking this environment difficult. Cells in normal culture conditions have a 
steady supply of oxygen and all cells in the monolayer have equal access to this oxygen. 
Hypoxia is a well known feature of the PDA microenvironment, shown to drive PDA progression, 
mediated by Hypoxia-inducible factor-1 (HIF-1) (Koong et al. 2000; Zhao et al. 2014). However 
the effect of hypoxia on cancer cells is variable and context dependent. Indeed many solid 
tumors have been shown to display cycling hypoxia, in which areas of tumors are deoxygenated 
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for long periods of time and later reoxygenated, making the effect of hypoxia on tumors difficult 
to both study and assess (Michiels, Tellier, and Feron 2016). Studies based on C13 labeling 
experiments have shown that hypoxic cells have increased flux through the dnFAS pathway 
when compared to normoxic cells (Holleran et al. 1995). On the other hand it has also been 
shown that scavenging pathways are induced by hypoxic conditions with cells relying less on 
dnFAS. Hypoxia induces lipid uptake by macropinocytosis in Ras driven cells (J. J. Kamphorst 
et al. 2013) and autophagy upregulation occurs in pancreatic cancer cells during intermittent 
hypoxia (Zhu et al. 2014). These studies indicate that the effect of hypoxia could be dependent 
on other factors. Perhaps in situations where extracellular lipids are abundant hypoxia induces 
macropinocytosis whereas when extracellular nutrients are scarce hypoxia prompts increased 
dnFAS and dependence on FASN. One way to test this hypothesis would be to look at cell 
viability, activity of FASN, and levels of macropinocytosis with and without extracellular lipid 
sources during hypoxia. Our in vivo observation that epithelial cells are sensitive to FASN 
inhibition may have to do with their location within the tumor and more specifically the nutrient 
limitations posed by the surrounding stroma.  
PDA cells have elevated rates of macropinocytosis when extracellular nutrients are 
available (Commisso et al. 2013; Jurre J. Kamphorst et al. 2015). In vitro cells have complete 
access to residual lipids from the media (1% charcoal stripped FBS) as well as to the remains of 
dead cells meaning that these cells have adequate means to sustain lipid deficiency. However 
in the PDA microenvironment of KPC mice, the dense stroma and reduced perfusion could limit 
access to these extracellular nutrients, leading to increased dependence of dnFAS and thus 
FASN activity. Indeed we show in KPC mouse tumors that areas with access to blood 
vasculature display lower FASN expression, while areas without blood vessels show increased 
expression (Figure 2.2). Both oxygen conditions and access to extracellular nutrients could 
explain the differences in sensitivity between PDA cell lines and KPC tumors during IPI-9119 
monotherapy. If, as the studies above indicate, microenvironment features such as hypoxia and 
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nutrient availability modulate the method through which cells derive lipids, then inhibition of 
dnFAS might be more effective when combined with inhibition of other lipid-providing pathways 
including macropinocytosis and autophagy. In this work we attempted to address both 
scavenging pathways through lysosomal inhibition in the hopes that this further restriction of 
lipids would induce higher levels of apoptosis.   
Scavenging	  pathways	  and	  FASN	  inhibition	  insensitivity	  
 
Our first step to investigate scavenging pathways was to inhibit both autophagy and 
macropinocytosis using chloroquine (CQ), an inhibitor of lysosomal degradation. When using a 
steady dose of CQ with a dose response treatment of IPI-9119, cell viability in all four PDA cell 
lines was reduced significantly (Figure 5.1). These studies indicate that regardless of FASN 
inhibition sensitivity, all cell lines require lysosomal degradation. We also found that the 
decrease in cell viability caused by dual IPI-9119 and CQ treatment was due to apoptosis, 
which was significantly increased in the majority of cell lines (Figure 5.2). We next attempted to 
further dissect the cause of this effect by specifically looking at autophagy and macropinocytosis 
during FASN inhibition.  
We assessed levels of autophagy and autophagosome flux in PDA cells in the presence 
and absence of FASN inhibition to see whether autophagy contributes to resistance to FASN 
inhibition.  The optimal method to assess autophagosome flux has been the subject of 
significant debate within the autophagy field. We made use of the most well-established assay 
to determine autophagosome flux: immunoblot detection comparing levels of LC3B-II before and 
after treatment with an autophagy inhibitor (Mizushima and Yoshimori 2007). Using this 
autophagosome flux method we assessed the change in autophagy over a 48-hour period with 
and without IPI-9119 treatment and determined no significant change (Figure 6). However there 
are several other methods to determine rates of autophagy. Another method that assesses the 
rate of autophagy in addition to the amount of autophagosomes present is a fluorescent 
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microscopy based assay in which a tandem fluorescent-tagged LC3B reporter plasmid is 
transfected into and stably expressed in the desired cell line. This novel reporter, mTagRFP-
mWasabi-LC3, can detect differences between lysosomes and autophagosomes based on the 
fact that fluorescent green and red proteins have different pH stabilities (C. Zhou et al. 2012; 
Kimura, Noda, and Yoshimori 2007). The green fluorescence of the mWasabi protein is 
quenched in the acidic environment of the lysosome while that of RFP is not, yielding yellow 
autophagosomes and red autolysosomes. When both red and yellow puncta are increased 
there is an increase in autophagosome flux as both autophagosomes and autolysosomes are 
higher in number. Increased yellow puncta without associated red puncta increase would be 
indicative of autophagy inhibition with a lysosomal acidification inhibitor, such as CQ. This assay 
would be able to more accurately determine the rates of autophagy in control vs. IPI-9119 
treated cells and would be a strong complementary method to quantify autophagic flux in future 
studies. 
After finding that autophagosome flux was not significantly increased using immunoblot 
analysis, we next used genetic ablation of autophagy to determine whether autophagy is a 
method through which FASN inhibited cells escape FASN inhibition. These assays were carried 
out in KPC mouse cell lines that, in addition to K-ras and p53 mutations, also possess a 
doxycycline inducible ATG4 dominant negative expression cassette. Induction of ATG4 
dominant negative expression had no effect on IPI-9119 dose response curves in three mouse 
cell lines (Figure 7). It is notable that mouse cell lines displayed a right shifted IPI-9119 dose 
response curve when compared to human cell lines, indicating that higher concentrations of IPI-
9119 are necessary for an effect. Typical dose response curves were also only present in two 
cell lines, 5896 and 6287, portraying that these cell lines are sensitive to IPI-9119 at high doses. 
One explanation for a right shifted curve could be the effect of doxycycline treatment on FASN 
expression in these cell lines. We saw that doxycycline treatment induced FASN expression in 
all three cell lines, which could account for the greater IPI-9119 concentration required to initiate 
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an effect on viability. Indeed, we saw the same effect on human PDA cell lines when treated 
with doxycycline, the reason why an experiment utilizing doxycycline induced shRNA FASN 
knockdown human PDA cell lines was abandoned. The differences in sensitivity to IPI-9119 
treatment in the different mouse cell lines could be explained by macropinocytosis. Indeed we 
saw the two human PDA cell lines least sensitive to FASN inhibition, ASPC1 and BXPC3, 
displayed decreases in cell viability and apoptosis in the context of dual FASN and 
macropinocytosis inhibition (Figure 8). Mouse cell lines sensitive to FASN inhibition also 
displayed reduced viability (~50% decrease) with IPI-9119 treatment compared with sensitive 
human cell lines (20-30% decrease). An explanation for this difference in effect could have to do 
with the higher proliferative capacity of the cell lines. PDA mouse cell lines anecdotally 
proliferate at higher rates than human cell lines, which might make them more dependent on 
dnFAS to create cell and organelle membranes. Indeed the more IPI-9119 insensitive human 
PDA cell lines ASPC1 and BXPC3 have lower proliferative rates than the IPI-9119 sensitive cell 
lines, Miapaca2 and PANC1 (Figure 5.3).  
After seeing no difference in IPI-9119 dose response curves with and without autophagy 
ablation we decided to co-treat autophagy ablated cells with CQ to determine if CQ’s effects are 
independent of autophagy. Indeed, CQ treatment induced drastic reductions in cell viability, 
similar to the effect we witnessed in human PDA cell lines (Figure 7). If this effect was only due 
to autophagy, the genetic ablation of autophagy would phenocopy CQ treatment. Thus we can 
infer that CQ’s inhibition of lysosomal acidification and degradation are inducing these changes 
in cell viability. Studies have shown that CQ exerts its chemo-preventative effects in an 
autophagy autonomous manner. Indeed CQ was found to sensitize two breast cancer cells to 
chemotherapy independent of autophagy, which was ablated using two different RNA silencing 
techniques (ATG12 shRNA and Beclin 1 siRNA) (Maycotte et al. 2012). Although CQ is 
commonly utilized experimentally as an autophagy inhibitor, CQ has effects independent of 
autophagy inhibition, specifically the inhibition of lysosomal fusion with endosomes, acidification, 
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and eventual degradation of these entities. CQ thus effectively inhibits autophagy and 
macropinocytosis, an endocytic pathway. More research is needed to determine the specific 
effects of CQ on the degradation of macropinosome content. In terms of cancer therapeutics, 
treatment with CQ is an effective strategy to inhibit macropinocytosis and autophagy, both of 
which are upregulated in the context of oncogenic K-ras and in PDA specifically.  
To dissect the contribution of macropinocytosis to the effect we witnessed with dual 
FASN and lysosomal inhibition, we next blocked macropinocytosis using inhibitor EIPA in the 
context of FASN inhibition. The two cell lines with no response to IPI-9119, ASPC1 and BXPC3, 
were sensitive to IPI-9119 in the context of macropinocytosis inhibition, suggesting that lipid 
compensation in these cell lines is occurring through macropinocytosis. Indeed these two cell 
lines, ASPC1 and BXPC3 displayed increased apoptosis when treated with IPI-9119 and EIPA, 
while cell lines sensitive to IPI-9119 monotherapy displayed similar levels of apoptosis with both 
monotherapy and dual therapy (Figure 8.1, 8.2). These findings suggest that extracellular 
scavenging is a determinant of FASN inhibitor sensitivity. Indeed concomitant inhibition of these 
two pathways may yield an effective therapeutic strategy for PDA with primary resistance to 
FASN inhibition.  
Experiments utilizing PDA cell lines have shown that the Miapaca2 cell line in particular 
exhibits high levels of macropinocytosis (Supplementary Figure 2). We found that these cells 
were affected substantially in a cell viability assay with dual therapy, however treatment with 
both IPI-9119 and EIPA induced only marginally higher levels of apoptosis as IPI-9119 
monotherapy (Figures 8.1, 8.2). PANC1 were insensitive to EIPA in the context of FASN 
inhibition indicating that these cells undergo very low levels of macropinocytosis. Levels of 
apoptosis with dual treatment in PANC1 cells were the same as those with IPI-9119 
monotherapy. Interestingly despite reports that BXPC3 cell undergo low levels of 
macropinocytosis, these cells were sensitive to EIPA in the context of FASN treatment (Nakase 
et al. 2015; Commisso et al. 2013). Explanations for this effect could be that while BXPC3 cells 
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undergo low levels of macropinocytosis, they are reliant on exogenous lipids obtained through 
this method while Miapaca2 cells are not.  Another explanation is that both ASPC1 and BXPC3 
cell lines induce macropinocytosis in the context of FASN inhibition in order to maintain lipid 
homeostasis. It is possible that FASN inhibition could be a molecular switch in these cell lines, 
activating the macropinocytosis pathway. Additional work is needed to determine if these cells 
do induce macropinocytosis. Future experiments should aim to assess levels of 
macropinocytosis in all cell lines with and without IPI-9119 treatment. Assays utilizing high 
molecular weight tetramethylrhodamine-conjugated dextran (TMR-dextran) that is administered 
to cell post-treatment have been successful in marking macropinosomes (Jurre J. Kamphorst et 
al. 2015; Commisso et al. 2013). It may be necessary in this case to calculate a rate of 
macropinocytosis over time using CQ to inhibit lysosomal degradation. By this method, rates 
between different cell lines can be calculated basally and with IPI-9119 treatment.  
Dual	  FASN	  and	  lysosomal	  inhibition	  in	  vivo	  
 
Our findings suggest that both FASN activity and scavenging are important features 
allowing the continued survival of PDA cell lines. To target these pathways in vivo we carried 
out a short-term study evaluating the effect of dual scavenging and FASN inhibition in the 
KPfl/flC mouse model of PDA. Treatment with HCQ and IPI-9119 resulted in increased apoptosis 
and decreased proliferation in mouse tumor tissue (Figure 9.2). Dual treatment was more 
effective than monotherapy as this treatment induced significant effects in bulk tissue. By 
blinded counting of dual stained epithelial and apoptotic cells we did not see a significant 
induction of apoptosis in IPI-9119 and HCQ treated mouse tumors, however visually areas of 
concentrated apoptosis and adjacent necrosis were evident (Figure 9.3). These findings indicate 
that combination therapy with FASN and lysosomal inhibitors is a relevant therapeutic strategy 
in the treatment of PDA. Dual treatment prompted a more substantial effect and both induced 
apoptosis and decreased proliferation. Indeed dual treatment in vitro induced a modest G1 
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arrest in FASN inhibition sensitive cell lines, a previously reported effect of FASN inhibition 
monotherapy (Figure 5.3). Based on our results it seems that while IPI-9119 monotherapy has 
effects on PDA cells and tumors, dual therapy yields a more pronounced effect and thus is a 
more effective treatment. Whether this is due to compensatory lipid scavenging through 
macropinocytosis remains to be seen. Indeed assays utilizing ex-vivo human PDA tumor slices 
and TMR-dextran have been successful in gauging levels of macropinocytosis in vivo (Jurre J. 
Kamphorst et al. 2015). It would be interesting to see whether tumor slices from IPI-9119 
treated KPC mice display higher levels of macropinocytosis than vehicle controls. Additionally it 
would be relevant to see if dual treatment with IPI-9119 and CQ inhibits the degradation of 
macropinosome products both in vitro and in vivo using this assay.   
One surprising result was the difference in the number of apoptotic cells detected in the 
epithelial compartment of the two different mouse models. KPC mice treated with IPI-9119 
displayed significant epithelial apoptosis in tumor tissue, while KPfl/flC mice did not. One 
possible reason for this difference seen in mouse models during FASN inhibition could be 
differences in FASN signaling based on p53 expression. P53 is a known regulator of lipogenesis 
in cancer (Parrales and Iwakuma 2016). It has been demonstrated that in breast cancer cells, 
mutant p53 can stimulate expression of FASN, among other lipogenic enzymes (Freed-Pastor 
et al. 2012). Wildtype p53 decreases expression of FASN, through SREBP1, and when p53 is 
deleted in this same model SREBP1 levels are restored (Yahagi et al. 2003). It is unknown how 
null p53 would influence FASN expression compared to mutant p53. If FASN expression were 
comparatively decreased when p53 is deleted, it is consistent that these cells would be less 
dependent on dnFAS and FASN activity, rendering them more insensitive to FASN inhibition. 
More research is needed to determine whether FASN expression levels are lower in KPfl/flC 
mouse tumors. KPfl/flC mouse tumors were sensitive to both HCQ and IPI-9119 dual therapy 
where apoptosis was seen in bulk tumor. An obvious next direction would be to treat KPC mice 
with both HCQ and IPI-9119.  
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Another possible next direction would be genetic ablation of FASN in vitro and in a 
mouse model. While IPI-9119 has been shown to be an effective and potent inhibitor of FASN 
activity, it would be relevant to determine if genetic ablation of FASN phenocopies IPI-9119 
treatment. As part of this project we attempted shRNA knockdown of FASN using doxycycline 
inducible cell lines, however doxycycline itself induces increased FASN expression. Another 
avenue to explore genetic ablation in vitro is the CRISPR/Cas9 system. In vivo FASN genetic 
ablation must be a time-point inducible model that can be activated in the adult mouse, as 
FASN is critical to fetal development (Chirala et al. 2003). Additionally expression would have to 
be targeted to the organ of interest using a tissue specific promoter, such as PDX-1, as global 
expression could cause unwanted effects in adipocytes and liver tissue. Thus creating a KPC 
mouse model with FASN genetic ablation could prove difficult and time consuming. An 
alternative could be to utilize 3D organoids, although these do not recapitulate the complete 
microenvironment of PDA. 
Conclusions	  
 
This is the first described use of a FASN inhibitor in an autochthonous mouse model of 
pancreatic cancer. We report a compartment specific effect in FASN expressing epithelial cells 
in the KPC mouse model indicating on-target effects of novel small molecule inhibitor, IPI-9119. 
This agent is able to effectively penetrate the desmoplastic stroma and induce apoptosis in 
distant scattered epithelial pockets. However treatment with IPI-9119 in vitro resulted in a less 
pronounced effect.  Marked differences in IPI-9119 sensitivity between in vitro and in vivo 
experiments suggest that the tumor microenvironment is a factor in lipid maintenance. 
Combination therapy with scavenging pathway inhibitors in vitro revealed that macropinocytosis 
maybe a compensatory lipid scavenging pathway in the context of FASN inhibition. Furthermore 
we found evidence that CQ acts as a lysosomal inhibitor, effectively blocking both autophagy 
and macropinocytosis. Dual inhibition of FASN and lysosomal degradation induced both anti-
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proliferative and apoptotic effects in KPfl/flC bulk tumors. These results indicate that lipid 
maintenance in PDA is complex involving the contribution of and compensation between de 
novo FA synthesis and scavenging pathways. Future directions should aim to dissect these 
roles further with the eventual goal of conducting a long-term in vivo survival studies to 

















Materials	  and	  Methods	  
 
Cell culture assays 
	  
Cell lines and cell culture 
ASPC1, BXPC3, Miapaca2, and PANC1 cell lines were obtained from ATCC and were tested 
for mycoplasma. Doxycycline-inducible ATG4BC74A-strawberry KPC mouse cell lines 5896, 
6287, and 6406, were isolated from mice by Dr. Annann Yang and gifted by Dr. Alec 
Kimmelman. Cells were maintained at 37ºC and 5% CO2. Cells were grown in Dulbecco's 
Modified Eagle Medium (DMEM) (Life Technologies, 11965-118) with penicillin and 
streptomycin (Corning, 30-003-CI) and 10% Fetal Bovine Serum (FBS) (Life Technologies, 
10438-034). For all assays cells were treated in 1% charcoal stripped FBS (Life Technologies, 
A3382101) instead of 10% FBS for the entirety of experiments.  
 
Cell viability assays  
Cells were plated in 96-well plates. PANC1 and Miapaca2 cells were plated at 4,000 cells per 
well; BxPC3 and AsPC1 cells were plated at 8,000 cells per well. Cells were seeded and left to 
grow overnight, and treated with the compounds listed the following day at the noted 
concentrations: IPI-9119 (Infinity Pharmaceuticals) dose response, Chloroquine (Sigma, C6628) 
7.5 µM, EIPA (Sigma, A3085) 10 µM. Compounds were formulated according to the 
manufacturer’s instructions. Cell viability assays were carried out using the AlamarBlue reagent 
(Thermofisher, 88952). In 96-well plates each well contained 150 µL of media upon which 15 µL 
of AlamarBlue reagent was added. Plates were incubated at standard culture conditions 




Cell cycle assays  
ASPC1, BXPC3, Miapaca2, and PANC1 cells were plated at 1,000,000 on 10 cm plates. Cells 
were seeded and left to grow overnight, and treated with the compounds listed the following day 
at the noted concentrations: IPI-9119 (Infinity Pharmaceuticals) 20 nM, Chloroquine (Sigma, 
C6628) 7.5 µM. Compounds were formulated according to the manufacturer’s instructions.  
After 48 hours cells were washed with PBS, trypsinized with .25% trypsin (Life Technologies, 
25200-056), and neutralized with 10% FBS in PBS. Cells were washed in PBS and fixed for 30 
minutes on ice in 70% ethanol. Pellets were resuspended in 5ul per million cells of 7-AAD 
reagent (Biolegend, 420404) and strained through a 40µM strainer (BD Falcon, 08-771-1).  
Cells were analyzed on a MACSQuant Analyzer 10. A minimum of 20,000 cells were analyzed 
per condition. Software analysis was carried out using FCS Express.  
 
Immunoblot assays 
ASPC1, BXPC3, Miapaca2, and PANC1 cells were plated at 500,000 for ASPC1 and BXPC3 
and 250,000 for Miapaca2 and PANC1 on 10 cm plates. Cells were seeded and left to grow 
overnight, and treated with the compounds listed the following day at the noted concentrations: 
IPI-9119 (Infinity Pharmaceuticals) 20 nM, Chloroquine (Sigma, C6628) 7.5 µM, EIPA (Sigma, 
A3085) 10 µM. Compounds were formulated according to the manufacturer’s instructions.  After 
48 hours cells were washed with PBS and lysed using 1x RIPA buffer with protease and 
phosphatase inhibitors. Lysates were prepared in 4x Laemmli sample buffer. Protein lysates 
were loaded into 20% SDS-page gels and resolved by electrophoresis. Samples were then 
blotted on PVDF membrane (Millipore IPVH00010) using the wet transfer technique (BioRad). 
Membranes were blocked in 5% BSA-TBST for 1 hour and incubated in primary antibody in 5% 
BSA-TBST at 4°C for 16 hours. Membranes were rinsed (3 x 5 min) in TBST and incubated in 
horseradish peroxidase-conjugated secondary antibodies in 5% BSA-TBST for 1 hour and 
rinsed again in TBST (3 x 5 min). Membranes were visualized using a camera. Primary 
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antibodies are as follows: Cleaved caspase-3 (Cell Signaling, 9664S), 1:1000 dilution; FASN 
(Cell Signaling, 3180S), 1:1000 dilution; LC3B (Cell Signaling, 3868S), 1:1000 dilution, Actin 
(Cell Signaling, 4970S), 1:1000 dilution. Secondary antibody: goat anti-rabbit HRP (Santa Cruz 
Biotechnology, sc-2004). Immunoblots were analyzed by densitometry analysis using ImageJ.  
	  
Animal breeding and generation of KPC and KPfl/flC mice 
KPC mice were bred as previously described (Hingorani et al. 2005; Olive et al. 2009) Studies 
with mice were carried out in accordance with the institutional guidelines of Columbia University. 
 
Biopsy study and short-term intervention studies 
Described in Figures (3.1, 3.3, and 9.1). Mice were randomized into studies.  
Drug treatments: HCQ at 60 mg/kg in 100 µL of PBS daily, IPI-9119 at 200mg/kg in vehicle 
twice daily.  
 
3-D Ultrasound 
Tumor volume quantification was carried out using 3-D ultrasound as previously described (S. 
A. Sastra and Olive 2013). 
	  
Pathology and immunohistochemistry 
Samples were fixed in formalin immediately and were washed in 70% ethanol 24 hours later 
and subjected to dehydration processing. They were next mounted in paraffin wax blocks and 
sectioned on a Leica RM 2235 at 5 µM thickness. Sections were mounted on charged slides 
and heated to 60ºC. Slides were then subjected to rehydration and antigen retrieval. Antigen 
retrieval was carried out for five minutes in boiling 10 mM sodium citrate buffer pH 6, .05% 
Tween-20 using a standard pressure cooker. Slides were allowed to cool to room temperature 
in an ice-cold water bath and then incubated in 3% hydrogen peroxide for 20 minutes at room 
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temperature to block endogenous peroxidases. Slides were blocked in 1.5% horse serum and 
2% animal free blocker (Vector Laboratories, SP-5030) for 1 hour at room temperature. Slides 
were then stained with a primary antibody overnight at 4ºC. Slides were then washed 3x with 
TBS-T. Secondary antibody Anti-Rabbit Immpress (Vector Labs, MP-7401) was applied for 30 
minutes at room temperature. Staining was developed using the DAB brown reagent (Vector 
Labs, VV-93951085) or the DAB purple reagent (Vector Labs, SK-4605).  
Primary antibodies: Cleaved caspase-3 (Cell Signaling, 9664S), 1:100 dilution; phosphohistone-
H3 (Cell Signaling, 9716S), 1:100 dilution; FASN (Cell Signaling, 3180S), 1:50, CD31 (Cell 
signaling, 77699S), 1:100 dilution, CK19 (Abcam, ab133496). Histological staining was carried 
out on paraffin sections (hematoxylin and eosin). Slides were scanned using Leica slide 
scanning software from the HICCC molecular pathology core. Counting was performed blinded 




Statistical analyses were performed as indicated on figures.  
Assays with dose response curves were the mean values +/- SEM from three biological 
replicates each consisting of four technical replicates. Using GraphPad Prism software 
log(inhibitor) vs. response curves were plotted using a four parameter variable slope model 
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